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A COMPARISON OF MAXIMAL EXERCISE RESPONSES AMONG PATIENTS WITH A TOTAL
ARTIFICIAL HEART, A LEFT VENTRICULAR ASSIST DEVICE, OR ADVANCED HEART FAILURE
By Justin McNair Canada, BS
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Health & Movement Sciences at Virginia Commonwealth University.
Virginia Commonwealth University, 2012.
Major Director: Ronald K. Evans, PhD, Associate Professor, School of Education, Health and
Human Performance Department

The purpose of this study was to evaluate graded exercise responses to treadmill
exercise in patients with a total artificial heat (SynCardia, Tucson, AZ). Additionally, this study
sought to compare the exercise response in total artificial heart (TAH) patients to both
advanced heart failure (HF) patients on medical management only and HeartMate II (Thoratec
Corp., Pleasanton, CA) left‐ventricular assist device (HMII) patients. For patients with
biventricular heart failure the TAH is a viable option to bridge patients until transplant becomes
available. Its demonstrated improvement in mortality and increasing usage necessitates a shift
in focus to quality of life in the TAH patient including functional ability. The evaluation of
cardiorespiratory responses to graded exercise provides an objective measure of functional
ability. There is very limited information in the literature on the exercise response of the

mechanical circulatory support (MCS) device patient, particularly the TAH patient. A review
was performed on MCS patients who underwent symptom‐limited cardiopulmonary exercise
testing (CPET) following device implant of either TAH or HMII. ANOVA was performed to
compare differences between the two device groups and HF patients listed for heart transplant.
Fourteen TAH patients underwent CPET (9 male, 5 female) with peak oxygen consumption
(VO2) of 0.926 + .168 L∙min, 36 + 8% % predicted, 11.0 + 2.3 ml.kg.min or 3.1 + 0.7 METs.
Ventilatory anaerobic threshold (VAT) was 0.706 + .181 L∙min. Peak VO2, % pred. VO2 and VAT
were significantly lower in the TAH compared with HMII and advanced HF (p = 0.0012, p =
0.0106, p = 0.0009, respectively). Peak RER was significantly higher (p = <.0001) and OUES was
significantly lower (p = 0.0004) in the TAH. Exercise capacity is significantly reduced in the TAH
patient below that observed in HMII LVAD and advanced HF patients. This provides a baseline
for expected functional status and has implications on the ADL tolerance of these individuals.
The next step is to develop strategies to ameliorate this continued exercise intolerance.
The documents herein contain a review of literature including a background in heart
failure and the use of the exercise response in the heart failure patient. An overview is also
presented on the use of MCS describing physiology, device function, and exercise physiology of
the MCS device patient. A manuscript has also been included detailing a cross‐sectional review
of the effects of graded exercise in the TAH patient and comparing it to the HMII and advanced
HF patient.

Introduction

Heart failure, which is a syndrome that includes circulatory congestion and/or
inadequate tissue perfusion, can be caused by any type of condition that damages the heart
and typically leads to debilitating symptoms of dyspnea, fatigue, and exercise intolerance. It
carries attributable risks, increasing incidence, an ominous prognosis, complex
pathophysiology, and can be a challenge to manage.1 The American Heart Association
estimates that there are 5.7 million Americans living with heart failure and 600,000 new cases
are diagnosed annually. 2 Lifetime risk of heart failure development is 1 in 5 for both men and
women, and hypertension is associated with 75% of all heart failure cases. 3, 4 Furthermore, the
incidence is highest among African‐Americans and it increases with advancing age. 5, 4 Risk
factors for the development of heart failure include coronary artery disease, hypertension,
cardiomyopathy, myocardial infarction (MI), obesity, diabetes, dyslipidemia, valvular heart
disease, renal insufficiency, sleep‐disordered breathing, and tachycardia. 1, 6 Antecedent MI and
hypertension are the most attributable risk factors. 3, 7 Approximately 50% of those diagnosed
with heart failure will die within 5 years and it carries a mortality risk that is four times that of
the general population of like age.7, 8 Lastly, heart failure is the most common hospital
discharge diagnosis and consumes more Medicare dollars than any other diagnosis.2, 7
1

Advanced heart failure therapies are available for patients with end‐stage disease who
are refractory to conventional medical management. This includes the use of inotropic agents,
heart transplantation, and mechanical circulatory support (MCS) devices.1 Heart
transplantation remains the definitive therapy for those with refractory end‐stage heart
failure.9 Unfortunately, the demand for heart transplants continues to significantly exceed the
supply of donor hearts.9 This has led to the increasing use of mechanical circulatory support
devices to keep patients alive until heart transplant.10 To date, the majority of MCS devices
implanted are left‐ventricular assist devices (LVAD) which unload the native heart’s left
ventricle and improve survival and quality of life.10 However, there is a subset of patients with
advanced heart failure that are not appropriate candidates for LVAD therapy due to right‐sided
heart failure or biventricular failure.11 For these patients, the SynCardia Total Artificial Heart
(TAH) is the most effective treatment therapy as a bridge to heart transplant.12 The TAH
consists of two pneumatically driven pumps that orthotopically replace the failing hearts native
ventricles.11
Typically, clinical evaluation of the heart failure patient includes identification of causes,
description of symptoms, evaluation of cardiac structure, and quantification of functional
status.13 Patients are stratified according to heart failure risk, presence of cardiac structural
changes, functional status, and presence of symptoms.13 This allows determination of
prognosis and guides management. In heart failure, cardiopulmonary exercise testing (CPET)
2

has proven to be a reliable tool to guide therapy, estimate prognosis, and evaluate patients for
heart transplant.14 Quantification of the exercise response in heart failure is valuable because
of its ability to determine prognosis and provide insight into the pathophysiological processes
of the disease state.15, 16 In healthy individuals, the ability to perform dynamic activities is
largely determined by the hearts ability to appropriately increase cardiac output to provide
adequate blood flow and oxygen to working muscles and organs.14 In heart failure, a reduced
cardiac output along with pulmonary congestion and deconditioning lead to impairment in the
ability to perform exercise17 therefore exercise intolerance is a hallmark symptom of heart
failure along with pulmonary congestion. The relationship between exercise performance and
heart failure severity has led to the use of exercise testing in the evaluation and management of
heart failure patients.
Due to its ability to stratify risk and accurately measure exercise capacity, CPET is
considered a core assessment of the heart failure patient.18 CPET variables have been shown to
correlate with cardiac function, pulmonary hemodynamics, and neurohormonal status.18
Standard CPET variables assessed in heart failure include peak oxygen consumption, ventilatory
anaerobic threshold, ventilatory efficiency slope, oxygen uptake efficiency slope, partial
pressure of end‐tidal carbon dioxide, presence of an exercise oscillatory breathing pattern, and
respiratory exchange ratio.19
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The utility of CPET after MCS device implant is less well‐established due to a scarcity of
information on this unique patient population. Most of the available literature describing
exercise in the MCS patient has been based upon 1st generation or pulsatile‐flow left ventricular
assist devices. There is, however, a distinct lack of studies examining the effects of exercise in
MCS device patients20 particularly the newer continuous‐flow LVAD devices. In regards to the
exercise response of the TAH patient there is an even further paucity of information with very
few studies available describing the functional status of the TAH patient.12, 21, 22‐24 Therefore, the
purpose of this study was to evaluate the cardiorespiratory responses to graded exercise in the
TAH patient. Additionally, we sought to compare those responses to responses obtained from
HeartMate II LVAD patients and non‐MCS device patients with advanced heart failure who had
been evaluated and accepted for heart transplantation. It is hypothesized that exercise
capacity, specifically the peak oxygen uptake, will be significantly reduced in heart failure
patients after TAH implant compared with HeartMate II LVAD patients and patients with
advanced heart failure un‐supported by MCS device. Additionally, it is hypothesized that an
abnormally elevated ventilatory response to exercise exists in the TAH patient due to the early
onset of acidosis. This will result in an increased ventilatory efficiency slope and a concomitant
reduction in the oxygen uptake efficiency slope in the TAH patient compared with HeartMate II
LVAD patients and patients with advanced heart failure un‐supported by MCS device. The
initial characterization of this exercise response along with comparisons to more common
4

patient populations will provide insight into the functional limitations of the TAH patient and
possible mechanisms for their exercise intolerance.
This thesis document has been organized to include a relevant review of the literature in
regards to heart failure and the use of CPET variables in HF evaluation & management.
Furthermore, this includes an overview detailing the use of MCS in advanced HF management,
the physiology and function of the MCS device, and lastly the exercise physiology of the MCS
device patient. A manuscript titled “A Comparison of Maximal Exercise Responses among
Patients with a Total Artificial Heart, a Left Ventricular Assist Device, or Advanced Heart Failure”
is also included describing a cross‐sectional retrospective analysis of symptom‐limited CPET’s
performed on the TAH patient which were compared with the HMII LVAD patient and non‐MCS
device patients with advanced heart failure. Additionally, within group comparisons were
performed to elucidate contributors to the exercise intolerance of these patient populations.

5

Review of Literature

Heart Failure
Heart failure is a clinical syndrome in which heart disease reduces cardiac output,
increases venous pressures, and is accompanied by molecular and other abnormalities that
cause progressive deterioration in cardiac function. 25 The American College of Cardiology/
American Heart Association Practice Guideline for the Diagnosis & Management of Heart
Failure defines heart failure as a complex clinical syndrome that can result from any structural
or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. 1
It can be characterized as the result of various etiologies which damage the heart and cause
impairment, disability and premature death. The cardinal signs/ symptoms of heart failure are
dyspnea, fatigue, exercise intolerance, and fluid retention which can lead to peripheral edema
and/or pulmonary congestion. Because not all patients with heart failure exhibit fluid
retention, the term “heart failure” is increasingly preferred over the historic term “congestive
heart failure (CHF)”.
Incidence
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In developed countries, heart failure has become epidemic. Based on recent American
Heart Association (AHA) statistics, there are 5.7 million American adults living with a diagnosis
of heart failure and 600,000 new cases of heart failure diagnosed annually. 2 The lifetime risk of
developing heart failure is 1 in 5 individuals for both men and women. 4 However, this lifetime
risk varies with the etiology of heart failure onset. At 40 years of age, the lifetime risk of heart
failure occurring without a preceding MI is 1 in 9 for men and 1 in 6 for women. 4
Seventy‐five percent of all heart failure cases are associated with a history of
hypertension. 4 African‐Americans appear to have the highest incidence of heart failure across
the races. 5 They also appear to have the highest heart failure incidence without antecedent
myocardial infarction. 5 The lifetime risk of developing heart failure for people with blood
pressure >160/90 mmHg is double that of those with blood pressure <140/90 mmHg. 4
Heart failure incidence is known to increase with age. The incidence of heart failure
approaches 10 per 1,000 people in those over the age of sixty‐five years and rises to > 40 per
1,000 people in those aged 85 years or older. 4 This has important implications given the rising
age of the U.S. population. The incidence of heart failure has been relatively stable over the
past 30 years. However, the prevalence of heart failure is increasing, which is felt to be in part
due to the aging of the population and the improved survival following myocardial infarction.
While the overall mortality rate of acute myocardial infarction (AMI) has declined this improved

7

survival may be increasing the prevalence of heart failure as antecedent MI is a known risk
factor for future development of heart failure. 26 Lastly, with the growing prevalence of
hypertension, and exponential increases in diabetes and obesity rates, which are both known
heart failure risk factors, may explain the increased prevalence of heart failure. 27
Burden
Heart failure imposes both a significant health as well as financial burden. In terms of
prognosis, approximately 50% of people diagnosed with heart failure will die within 5 years. 8
In 2007, heart failure was associated with a mortality of 277,193 individuals (121,684 males and
155,509 females). Data from the Framingham Study suggested that of those with clinically‐
manifest heart failure, the median survival was only 1.7 years for men and 3.2 years for women,
with only 25% of men and 38% of women surviving 5 years. This is a mortality rate 4 times that
of the general population of the same age. 7
In terms of financial burden, heart failure is the most common hospital discharge
diagnosis in adults over the age of sixty‐five years in the United States. Heart failure is
accountable for 1,000,000 hospitalizations per year and costs more than $25 billion. 2 Heart
failure is the most common Medicare hospital discharge diagnosis‐related group, and more
Medicare dollars are spent for the diagnosis and treatment of heart failure than for any other
diagnosis. 26
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Etiology
Heart failure (HF) can be caused by any type of condition that damages the heart. There
are a host of known risk factors for heart failure including coronary heart disease, hypertension,
cardiomyopathy, prior myocardial infarction, obesity, diabetes, lipid abnormalities, valvular
heart disease, renal insufficiency, sleep‐disordered breathing, and tachycardia. 1, 6
Coronary Heart Disease

Based on National Health and Nutrition Examination

Survey I (NHANES I) data, He and colleagues concluded that more than 60% of the heart failure
that occurs in the general U.S. population might be attributable to coronary heart disease. 28
Hypertension Additionally, data from the Framingham study have shown that
hypertension precedes heart failure in 91% of patients. 3 In contrast to the NHANES I data, the
Framingham study credited hypertension with the highest population attributable risk (PAR) for
heart failure, accounting for 39% of the risk in men and 59% of the risk in women. 7
Myocardial Infarction

Prior myocardial infarction seems to account for 34% and

13% of heart failure risk in men and women, respectively. 7
Obesity

In the Physicians Health Study, the risk of heart failure increased 11% for

every 1‐unit (kg/m2) increase in body mass index (BMI). Body weight status categorization
revealed overweight participants have a 49% increased HF risk and obese individuals carry a
180% increased risk of heart failure compared with lean individuals (BMI <25). 29
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Diabetes

Approximately 19% of those with heart failure have diabetes and it

appears to account for 6 – 12% of HF incidence based on the Framingham study data. 7 Poor
glycemic control appears to have a positive relationship with HF risk. Iribarren and colleagues
found that for every 1% increase in glycosylated hemoglobin (HgbA1c) the risk of heart failure
increased by 8%. 30
Lipid Abnormalities

There appears to be a significant association between abnormal

lipid profiles and incidence of heart failure. Sampietro et al. found a strong and independent
association between low high‐density lipoprotein (HDL) levels and the presence of dilated
cardiomyopathy. 31 They suggested low HDL levels may play a role in the endothelial‐
microvascular dysfunction seen in idiopathic dilated cardiomyopathy.
Valvular heart diseaseValvular heart diseases more than doubles the risk of HF but is
present in only 5% of the population so that only 7% of HF can be attributed to this cause. 7
Impaired renal function

Renal insufficiency is related to a higher risk of new‐onset

heart failure even after adjusting for traditional risk factors. This risk also tends to increase
based upon worsening of renal function. 32
Sleep disordered breathing

Sleep disordered breathing confers an increased risk of

heart failure development. 33 Javaheri et al. describes a prevalence of central sleep apnea (CSA)
in 40% and obstructive sleep apnea (OSA) in 11% of heart failure patients. 34 The reason for this
increased risk seems to be multifactorial in regards to pathophysiology, but also persists after
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accounting for associated risk factors. 35 Sympathetic nervous system activity dependent upon
sleep phases is disturbed by recurring episodes of apnea. In sleep apnea at the end of each
apnea episode, sympathetic activation reaches a maximum level. Recurrent hypoxemic stress
seems to increase endothelin secretion and induces vasoconstriction. Catecholamine levels are
also elevated. 36
Tachycardia

Tachycardia‐induced cardiomyopathy also confers increased risk of heart

failure. 37 The Framingham Heart study demonstrated that for every 10‐beat per minute
increase in heart rate there was a >10% higher risk for heart failure. 7
Other traditional well‐known modifiable coronary artery disease risk factors are
associated with heart failure risk. Current cigarette smoking was found to be a major
independent risk factor for development of heart failure in NHANES I. 28 Smoking was
associated with a relative risk of 1.45 and the relationship was independent of hypertension,
body weight, and other heart failure risk factors. This indicates that the direct effects of
smoking on heart failure are more than that attributed to its known coronary heart disease risk
impact.
Lack of physical activity or physical inactivity has also been shown to be an important
risk factor for heart failure development. 28 Higher levels of physical activity are well‐known to
confer a reduced risk of antecedent heart failure risk factors such as CAD, hypertension,
diabetes, and obesity. 38 After adjusting for known antecedent HF risk factors, NHANES I found
11

that physical inactivity accounted for a population attributable risk for heart failure of
approximately 9%. 28 It is unclear, however, if a direct relationship exists between heart failure
and physical activity levels.
Lastly, depression has also been linked to heart failure incidence. Depressed elderly
patients have been shown to have a two‐fold higher likelihood of developing heart failure. 39
Pathophysiology
The signs/symptoms of heart failure are mainly the result of hemodynamic
derangements. These derangements are influenced by neurohumeral abnormalities, cardiac
remodeling, and cellular and molecular abnormalities. 25
The ability of the heart to pump blood is reduced in heart failure. Cardiac performance
is influenced by heart rate, the volume of blood ejected with each heartbeat, and the pressure
at which the blood is ejected. The volume of blood ejected with each heart beat is termed the
stroke volume. Stroke volume is the result of end‐diastolic volume (EDV) minus end‐systolic
volume (ESV). Cardiac output is the product of stroke volume x heart rate. It is the total
amount of blood pumped by the heart per minute. 25
The pressure at which the blood is ejected is related to the filling properties and ejection
capabilities of the ventricle. Ventricular filling is determined by venous return or pre‐load, end‐
systolic volume from the previous heartbeat, and the ability of the ventricle to relax. The
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ejection capabilities of the ventricle depend upon the arterial pressure (MAP) or after‐load,
end‐diastolic volume prior to systole, and the contractility of the ventricle. 25
The reduced cardiac output seen in heart failure may be due to a derangement in the
cardiac cycle (i.e. heart rate), failure of the ventricle to properly contract during systole, and/or
failure of the ventricle to properly relax and fill during diastole. The systolic dysfunction seen in
heart failure is characterized by abnormalities in the basic properties that determine stroke
volume. 6 This includes contractility, myocardial mass, pre‐load or EDV, and after‐load or MAP.
Contractility is the ability of myocardial tissue to generate force. Ejection fraction,
which is the percentage of the end‐diastolic volume that is ejected during systole, is most
commonly used to assess contractility or systolic function. However, ejection fraction is also
influenced by pre‐load, afterload, and myocardial mass. Ejection fraction is a known strong
prognostic indicator in heart disease. 40 An ejection fraction of < 40% is considered reduced or
depressed and associated with poor outcomes. 41, 42
Myocardial mass is influenced by the degree of compensatory cardiac hypertrophy that
takes place in heart failure. Left‐ventricular hypertrophy is usually described as either
concentric hypertrophy due to pressure overload and/or eccentric hypertrophy due to volume
overload. Left‐ventricular hypertrophy is an adaptive response wherein the myocardium
compensates for increasing ventricular wall stress from either pressure and/or volume overload
13

according to Laplace’s law. Laplace’s law states wall stress or tension is dependent upon LV
pressure and/ or LV size (radius) and is defined by the following equation: Wall stress =
(pressure x radius)/ wall thickness. 43 Concentric hypertrophy results in increased ventricular
wall thickness without a change in ventricular chamber size. Eccentric hypertrophy results in
increased ventricular chamber size without an accompanying change in wall thickness. 25
Pre‐load is dependent upon venous return which affects end‐diastolic volume which in
turn affects myocardium sarcomere stretch. 44 After‐load is the force that myocardium must
overcome in order to contract. As after‐load increases contraction decreases leading to an
increased end‐systolic volume thus decreasing stroke volume. 44
The diastolic dysfunction seen in heart failure is a result of impaired ventricular
relaxation and filling. Diastolic filling is driven by the left‐atrial (LA) to left‐ventricle (LV)
pressure gradient. 44 This pressure gradient is dependent upon myocardial relaxation, LV elastic
properties, LV elastic recoil, LV contractile state, LA pressures, ventricular interaction,
pericardial constraint, LA elastic properties, pulmonary veins, and mitral orifice. 6 The failure of
the ventricle to relax maybe in part due to enhanced sympathetic tone. 6
Although the key feature of heart failure is the inability of the heart to act as a pump,
secondary adaptive responses to maintain short‐term cardiac performance lead to
maladaptation’s that contribute significantly to the long‐term progression of heart failure. 45
14

These maladaptations due to the onset of heart failure occur in the peripheral circulation, the
kidneys, skeletal muscle, and almost every other organ of the body. 41
Neurohumeral Abnormalities

Neurohumeral abnormalities greatly influence the

progression of heart failure. Early in heart failure, there may be a decrease in cardiac output,
arterial pressure, and baroreceptor activity, leading to an adaptive increase in excessive
neuroendocrine drive. The sympathetic nervous system is activated early, followed by
activation of the renin–angiotensin–aldosterone system (RAAS). 45 This leads to heightened
levels of neurohumeral vasoconstrictors such as norepinephrine, angiotensin II, endothelin,
vasopressin, neuropeptide Y which leads to increased systemic vascular resistance. Sodium and
water retention also occur due to RAAS activation to maintain cardiac output and arterial blood
pressure which comes at the expense of chronically elevated neuroendocrine activation. 41 This
leads to desensitization of sympathetic modulation and a decreased vagal tone. The reduction
of parasympathetic control is a hallmark sign of how heart failure affects the central nervous
system and is demonstrated by a loss of heart rate variability. 46 Figure 1 illustrates the
activation of the RAAS system.
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Figure 1: Activation of the renin‐angiotensin‐aldosterone system (RAAS).

Cardiac Remodeling

Maladaptive remodeling of cardiac myocyte size and

shape begins long before clinical heart failure. 47 Increased myocardial work from excess
pressure‐loading, volume‐loading or ischemia causes alterations in cardiac myocyte proteins
and architectural changes to ventricular myocardium.48, 49 Cardiac myocyte hypertrophy occurs
to compensate for the elevated ventricular wall stress. This causes structural change to the
ventricular myocardium and leads to augmented ventricular mass, chamber size, and further
deterioration of pump function. Collagen deposition in the cardiac interstitium is also a
contributor to impaired ventricular function and structure. 50

The neuroendocrine activated

vasoconstrictors and RAAS system also facilitate this collagen deposition. 51
Cellular and Molecular Abnormalities

Skeletal muscle abnormalities in addition to

myocardial abnormalities are well described in those with chronic heart failure.52, 41 Heart
failure alters skeletal muscle contraction at the level of the myosin‐actin cross‐bridge thereby
16

adversely affecting muscular performance. 52 This is felt to be one of the primary contributors
to the exercise intolerance of the heart failure patient. 41
Evaluation
There is no single tool for the diagnosis of heart failure. Patient evaluation often
includes: functional evaluation, cardiac structure evaluation, laboratory assessment, and
symptomology. 1 Most heart failure patients initially present to a healthcare provider in one of
three ways: a syndrome of exercise intolerance, fluid retention disorder, or with signs or
symptoms of another cardiac disorder. 1 Identification of possible causes of the heart failure is
first in the evaluation process and starts with the standard history & physical examination. 1
A staging system has been developed to classify patients with heart failure that takes
into account both the development and progression of the disease. 13 Patients are staged as A,
B, C, or D as follows: heart failure risk (Stage A), structural changes to the heart although
asymptomatic (Stage B), past or current heart failure symptoms accompanied by structural
heart disease (Stage C), and those with refractory heart failure that do not respond to
conventional treatment (Stage D) who may benefit from more advanced heart failure
strategies. This strategy allows for more specific treatment depending upon stage to reduce
mortality and morbidity. 13
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Patients’ functional abilities are often characterized based on the New York Heart
Association (NYHA) classification scale which is a subjective assessment of activity tolerance. 53
The NYHA functional classification scale assigns patients to one of four classes based on
presence of symptoms and limitations with varying levels of activity. It is, however, associated
with a significant degree of inter‐observer variability and does not reflect changes in exercise
capacity. 54 As a result, more objective indicators of functional status including the distance
that a patient can walk in six‐minutes (6MWD) and measurement of peak oxygen consumption
with maximal exercise testing are utilized. 16 Peak oxygen consumption with exercise testing is
considered a key prognostic indicator in patients with heart failure. 14 Evaluation of other
exercise‐related variables reflecting cardiac output, central nervous system function, and
ventilation provide additional powerful prognostic information in the heart failure population.16
Evaluation of cardiac structure allows for identification of mechanisms leading to heart
failure. The most common and useful diagnostic test to assist in the evaluation of heart failure
is the two‐dimensional echocardiogram coupled with Doppler‐flow to detect cardiac
abnormalities. 1 This allows evaluation of the myocardium, determination of ejection fraction,
ventricular structure, valve‐function, pericardium, and which chamber(s) are involved.
Hemodynamic data such as atrial and ventricular filling pressures and stroke volume can also be
estimated with the use of this modality. 55
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Laboratory assessment can identify factors contributing to or exacerbating the
progression of heart failure. Evaluation of patients with heart failure includes a complete blood
count, urinalysis, serum electrolytes, glycosylated hemoglobin, lipid profile, tests of both renal
and hepatic function, a chest radiograph, and a 12‐lead electrocardiogram. 1 Assessment of
thyroid function and screening for human immunodeficiency virus is also recommended 1.
Evaluation of the neurohormone brain‐natriuretic peptide (BNP) is an accepted part of clinical
practice in heart failure evaluation and is used to guide management. 56 Elevated BNP is
associated with elevated ventricular filling pressures, ischemia, and ventricular hypertrophy.
Reduction of BNP is also associated with improved clinical outcomes. 56
Assessment of volume status is also critical in the heart failure evaluation. The presence
of fluid retention is monitored through measurement of body weight, blood pressure, jugular
venous distention, peripheral edema, and organ congestion. Volume status assessment helps
determine the need for diuretic therapy and can be used to guide drug‐therapies used to treat
heart failure. 1
Identifying the presence and the extent of symptoms is part of the heart failure
evaluation. Common signs and/or symptoms of heart failure include dyspnea, fatigue,
orthopnea, nocturnal dyspnea, and exercise intolerance. Orthopnea is a difficulty in breathing
that occurs while the patient is lying down. Nocturnal dyspnea is a shortness of breath that
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occurs while sleeping which improves with sitting or standing upright. Complaints of chest
discomfort also require evaluation as up to two‐thirds of patients with heart failure are known
to have coronary artery disease. 57 It is noted, however, that up to one‐third of patients with a
non‐ischemic cardiomyopathy also report chest discomfort symptoms. 1 The type of symptoms
present can influence patient management. 58 Symptoms often attributed to heart failure can
also be due to other contributing comorbid conditions such as obesity, deconditioning, anemia,
and/or pulmonary disease. Cardiopulmonary exercise testing can assist in the determination of
symptomology. 14
Management
The management of heart failure consists of trying to reverse the potential causes,
ameliorate the symptoms, improve quality of life, and improve prognosis. 6 A number of
different evidence‐based pharmacologic agents, nonpharmacologic therapies and/or electronic
devices have demonstrated efficacy in heart failure management. 1 Advanced heart failure
therapies are available to those who are refractory to conventional management. 1
Risk Factor Management
Management of identified risk factors includes improving blood pressure control in
hypertensives, lowering blood glucose in those with insulin resistance or diabetes, as well as
improving the overall cardiovascular profile in those with CAD or substantial CAD risk.
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Achievement of optimal blood pressure control can reduce risk of heart failure by 50%, this risk
is decreased even further in those who improve blood pressure control following myocardial
infarction. 59 Individuals with hypercholesterolemia or CAD should similarly lower lipid levels. 59
Removal of potential causes of myocardial injury (i.e. smoking, excess alcohol consumption,
cocaine or stimulant use) is also recommended although this has not been shown to directly
decrease heart failure risk. 1
Pharmacologic Agents
Diuretics are considered a cornerstone of heart failure therapy because most patients
present with some form of organ congestion. 13 Diuretics improve the signs and symptoms of
heart failure despite little evidence to support their efficacy or impact on survival. 13 They work
primarily by removing excess salt and water thus lowering filling pressures and relieving
congestion. Excess fluid restriction and reduction of sodium intake are also standard heart
failure recommendations to achieve a similar outcome.
Digitalis glycosides which have been around for over 200 years also improve heart
failure outcomes. They have been shown to improve quality of life, reduce symptoms, and
increase exercise tolerance in individuals with heart failure in several placebo‐controlled trials.
60

Digitalis seems to act as both an inotropic agent as well as attenuating the RAAS system.
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Because of the known effects of the RAAS system on heart failure, pharmacological
agents targeting this system are an integral part of heart failure management. Specifically,
inhibiting the conversion of angiotensin I to angiotensin II, and blocking the angiotensin and
aldosterone receptors has been shown to alleviate symptoms, improve clinical status, and
reduce risk of death and hospitalization in patients with heart failure. 1 Angiotensin‐converting
enzyme inhibitors (ACE‐Inhibitors) are the most widely studied of all heart failure agents and
the recommended first choice RAAS inhibitors. 1
Increased sympathetic nervous system activation is one of the most important factors
responsible for the progression of heart failure. It seems intuitive that agents which block
sympathetic activity would improve heart failure prognosis. However, historically, it was
thought that beta‐adrenergic receptor antagonists (i.e. beta‐blockers) would worsen heart
failure due to their negative inotropic effects and in essence further compromise hemodynamic
status. 6 Results of large‐scale clinical trials have clearly demonstrated the efficacy of beta‐
blockers in the treatment of heart failure. 1 All‐cause mortality risk is decreased on the order
of approximately 35% in heart failure patients on beta‐blockers. 61
Vasodilators such as isosorbide dinitrate and hydralazine also show efficacy in heart
failure management in specific subgroups. Post‐hoc analysis of the Vasodilator‐Heart Failure
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Study (V‐HeFT) demonstrated African‐American heart failure patients derived a significant
benefit from these agents. 62
Nonpharmacologic Therapies
Cardiac resynchronization therapy (CRT) is yet another therapeutic option for
persistently symptomatic heart failure patients. Dyssynchrony between the heart chambers is
an important determinant of both systolic and diastolic function. Dyssynchrony is defined with
a surface electrocardiogram wherein the QRS complex duration is greater than 120
milliseconds. The consequences of dyssynchrony include suboptimal ventricular filling, a
reduction in the rise of ventricular contractile force or pressure, prolonged duration of mitral
regurgitation, and paradoxical septal wall motion. 63 There is strong evidence to support the
use of CRT in symptomatic heart failure patients to improve cardiac dyssynchrony. 1 CRT has
been shown to improve quality of life, six‐minute walk distance (6MWD), peak oxygen
consumption (VO2), NYHA functional class, and ejection fraction. 64
Heart failure patients who have evidence of ventricular tachydysrhythmias or who are at
risk of sudden cardiac death may also benefit from implantation of an automatic implantable
cardioverter defibrillator (AICD). 1 AICD implantation is indicated in survivors of cardiac arrest.
It is also indicated in NYHA Class II or III heart failure patients with an ejection fraction of < 35%
who have good functional status and a good 1‐year prognosis. 65
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Exercise training is recommended as an adjunct to pharmacotherapy for chronic stable
heart failure patients. 1 Historically, it was thought exercise training would accelerate the
progression of ventricular dysfunction. 66 This, however, is not the case with more recent
evidence actually showing the reverse. Haykowsky et al. performed a meta‐analysis of the
effect of exercise‐training on left ventricular remodeling and found aerobic exercise actually
reverses LV remodeling. 67 The Heart Failure: A Controlled Trial Investigating Outcomes of
Exercise Training (HF‐Action) trial also demonstrated the efficacy as well as the safety of
exercise‐training in individuals with heart failure. 68 This study found that exercise training was
associated with modest, but significant, reductions in overall and cardiovascular mortality and
hospitalization despite significant non‐adherence to the exercise programs.
Advanced Heart Failure Therapies
Advanced heart failure therapies are available for patients with end‐stage disease who
are refractory to conventional medical management. This comprises patients who are
considered Stage D and symptomatic at rest (NYHA IV) and exhibit significant functional
limitations. Therapies include continuous positive intravenous inotropic agents, mechanical
circulatory support, and or heart transplantation.
Positive intravenous inotropic agents are often utilized to manage Stage D patients who
are frequently hospitalized and require inotropic support to improve cardiac performance and
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promote stability. 1 This can help prevent deterioration of patients awaiting heart
transplantation and/or allow these patients to be discharged for palliative care. 1
Heart transplantation remains the definitive therapy for those with refractory end‐stage
heart failure. 9 Heart transplantation is indicated in those with a very‐poor one year prognosis.
69

The one year survival rate after heart transplant is approximately 88% with a median 50%

survival rate approaching 11‐years. 70 Heart transplantation also improves quality of life with
75% of recipients reporting a healthy lifestyle or only a few disease symptoms within the first
years after transplant. 70 Unfortunately, the demand for heart transplants continues to
significantly exceed the supply of donor hearts.9 The number of heart transplants being
performed peaked in the mid‐1990’s and has remained relatively stable in the current decade
at around 4,000 per year world‐wide and around 2,000 per year in the United States. 70 The
time spent waiting for a heart transplant as well as the severity of illness of the patient awaiting
transplant has increased. 9 This has led to the increasing use of mechanical circulatory support
devices to keep patients alive until heart transplant. 10
Mechanical circulatory support (MCS) is increasingly being utilized as a bridge to heart
transplant as well as a therapeutic option for patients with late or end‐stage heart failure who
does not respond to conventional medical management. The Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS), a National Heart, Lung and Blood
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Institute (NHLBI) sponsored collaborative database shows that 2,868 patients have received
implantation of one or more durable MCS devices between June 2006 and September 2010. 10
The number of MCS devices has increased from 100 total implants per year in 2006 to 668 total
implants per year through June of 2010, a 568% increase.10 The majority of MCS devices
implanted are left‐ventricular assist devices (LVAD) which unload the native heart’s left
ventricle and improve survival and quality of life. Current overall 1‐year/2‐year survival for
LVAD patients is 79% & 66%, respectively. 10 Due to the improving survival and acceptability of
patients on MCS devices they are also being utilized as so‐called “destination‐therapy” for
patients with refractory heart failure who are not candidates for heart transplantation, but
desire prolonged survival and improved quality of life. 10
Exercise Response in Heart Failure
Exercise intolerance is a cardinal manifestation of heart failure. 71 The exercise response
is important because it is known that resting measures of cardiac function (i.e. ejection fraction,
diastolic filling) do not correlate well with aerobic exercise capacity. 72 Measurement of the
exercise response is well‐established in heart failure due to its use as a prognostic indicator and
for the selection process of transplant recipients. 71, 73
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Use of the exercise response in Heart Failure Evaluation & Management
A number of exercise test variables have shown strong independent prognostic ability as
well as the ability to assess therapeutic efficacy in the heart failure population. 16 Due to its
ability to stratify risk, exercise stress testing with ventilatory gas‐analysis, commonly referred to
as cardiopulmonary exercise testing (CPET) is considered a core assessment of the heart failure
patient. 18 CPET variables have been shown to correlate with cardiac function, pulmonary
hemodynamics, and neurohormonal status. 18 Common CPET variables assessed in heart failure
include: peak oxygen consumption, ventilatory anaerobic threshold, ventilatory efficiency
slope, oxygen uptake efficiency slope, partial pressure of end‐tidal carbon dioxide, presence of
oscillatory breathing pattern with exercise, and respiratory exchange ratio. 19
Important Exercise Variables Evaluated in Heart Failure
Peak Oxygen Uptake (Peak VO2)
Maximal oxygen uptake is the product of cardiac output (C.O.) and arteriovenous
oxygen difference (a‐VO2) at maximal physical exertion as shown through a rearrangement of
the Fick equation wherein VO2 = (heart rate x stroke volume) x a‐VO2. Maximal oxygen uptake
is determined by measuring the volume and oxygen content of expired air. 74 It is calculated
using the following equation: VO2 = VE (FIO2 – FEO2) where VE = expired air, FEO2 = directly
measured fraction oxygen in expired air, FIO2 = directly measured fraction oxygen in inspired
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air. Additionally, VO2 is often expressed in metabolic equivalents (METs), with 1 MET
representing the resting energy expenditure (≈3.5 mLO2∙kg−1∙min−1). Because the term VO2max
implies that a physiological limit or plateau has been reached, which is commonly not the case
in clinical populations, the term peak VO2 is used clinically to define aerobic exercise capacity. 75
Peak VO2 is attractive clinically in heart failure because of its linear relationship with cardiac
output. 15 Peak VO2 has consistently shown to be a strong independent predictor of outcome in
heart failure and is the most widely recognized exercise variable in the heart failure
literature.16, 71
A landmark study by Mancini and colleagues demonstrated the utility of peak VO2 to
determine which patients benefit the most from heart transplantation. This study showed
ambulatory heart failure patients with a peak VO2 of > 14 milliliters per kilogram of body weight
per minute (ml.kg‐1.min‐1) could safely defer heart transplantation. 76 Since the Mancini study,
over 200 subsequent published studies have validated the use of cardiopulmonary exercise test
variables to predict prognosis in heart failure. 71 A peak VO2 of < 14 ml.kg‐1.min‐1is a recognized
probable indication and < 10 ml.kg‐1.min‐1 a definite indication for heart transplant listing. 69
More recently, the use of beta‐blockade in heart failure which improves outcomes has led to
the use of a peak VO2 < 12 ml.kg‐1.min‐1 as recommended criterion for heart transplant listing. 73
Peak VO2 along with anaerobic threshold is also used to classify the severity of heart failure and
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estimate cardiac reserve based upon the Weber functional classification system (Class A, B, C,
and D). 17 Table 1 is illustrates the Weber Functional classification.
Table 1: Classification of Exercise Cap acity in Patients
With Heart Failure, Based on Peak Oxy gen Up take and
Ventilatory Anaerobic Threshold

Class
Impairment
VO2 max
AT
A
None to Mild
> 20
>14
B
Mild to Moderate
16 ‐ 20 11 ‐ 14
C
Moderate to Severe 10 ‐ 16
8 ‐ 11
D
Severe
< 10
<8

Ventilatory Anaerobic Threshold
The ventilatory anaerobic threshold (VAT) is a submaximal indicator of cardiopulmonary
function. This is based on the concept that at a given work rate, oxygen supply alone to the
muscle does not meet the energy requirements. This imbalance increases the dependence on
anaerobic glycolysis for energy output, with lactate as a final metabolic byproduct.
Measurement of the VAT through ventilatory gas‐analysis is based on the premise that specific
changes in ventilation correlate with the progressive onset of lactate accumulation or the
lactate threshold. 77 The VAT is reduced in heart failure, correlates with disease severity, and
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has been shown to strongly predict prognosis. 78 An AT of < 11 ml.kg‐1.min‐1 indicates increased
risk in heart failure. 78
Ventilatory Efficiency Slope (VE/VCO2 slope)
The most widely used index of ventilatory efficiency is the VE/VCO2 slope. It is expressed
in units relative to the amount of minute ventilation in liters of air required to eliminate one
liter of carbon dioxide. Optimally, it is assessed continuously from the start of exercise until
peak exercise. 16 A normal VE/VCO2 slope is between 20 and 30, with values above 30 considered
abnormal.79 An elevated VE/VCO2 slope indicates worsening prognosis in heart failure. 16 A
VE/VCO2 slope > 35 is considered an acceptable indication to list for heart transplant. 73 The
VE/VCO2 slope is a reflection of the pathophysiology of an abnormal ventilatory response to
exercise in heart failure. Ventilation during exercise in heart failure is inefficient due to
ventilation‐perfusion mismatching, early lactate accumulation, and deconditioning.71 The slope
of the relationship between minute ventilation and carbon dioxide elimination (VE/VCO2 slope) is
superior to peak VO2 in predicting heart failure outcomes. 80 Arena et al. compared the
prognostic ability of peak VO2 with the VE/VCO2 slope and found the VE/VCO2 slope was better
able to predict cardiac‐related mortality in heart failure patients. 80
Oxygen Uptake Efficiency Slope (OUES)
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The oxygen uptake efficiency slope (OUES) is yet another marker of ventilatory efficiency
shown to have prognostic significance in heart failure.19 It describes a non‐linear ventilatory
response to exercise and is the quotient of the logarithmic transformation of minute ventilation
to oxygen uptake. It seems to be best defined as a regression slope (y = mx + b) and has
usefulness as both a submaximal and maximal exercise test variable. 81 The OUES is reduced in
heart failure patients compared with normal individuals. Lower values are associated with
worsening prognosis although it seems to be influenced by body mass index.82 In yet another
study of ventilatory efficiency in heart failure, Arena and colleagues identified optimal
prognostic threshold values for OUES that were dependent upon BMI. Cut‐off values of < 1.2, <
1.5, and < 1.7 identified increased risk in normal weight, overweight, and obese heart failure
patients, respectively. 82
Partial pressure of end‐tidal carbon dioxide (PetCO2)
Matsumoto and colleagues found the partial pressure of end‐tidal carbon dioxide
strongly correlated with cardiac output both at rest and during exercise in patients with heart
failure. They found the sensitivity and specificity of PetCO2 to predict an inadequate cardiac
output response to exercise at the respiratory compensation point were 76.6% and 75%,
respectively. 83 Normal resting values are 36 – 42mmHg and usually increase by 3 – 8mmHg
with moderate intensity exercise. 79 Resting values < 33mmHg, exercise values at the
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ventilatory anaerobic threshold < 36mmHg, and the inability to increase by at least 3mmHg
with moderate level exercise indicates poor prognosis in heart failure. 84

Exercise Oscillatory Ventilation (EOV)
Approximately 30% of patients with heart failure exhibit an oscillatory breathing pattern
to exercise. 85 Although its etiology is unclear, it seems to be related to abnormal CNS control
of ventilation due to the pathophysiology of heart failure.86 It is characterized by a periodic rise
and fall in ventilation without apnea similar to Cheyne‐Stokes respiration. 87 Corra et al defined
exercise oscillatory ventilation (EOV) as cyclic fluctuations in minute ventilation at rest that
persist into exercise lasting at least 60% of the total exercise duration, with an amplitude of >
15% of the average resting value of minute ventilation. The presence of this abnormal
breathing pattern portends a very poor prognosis in heart failure patients. 85 EOV has also
shown to be strongly predictive of sudden cardiac death. 88
Respiratory Exchange Ratio (RER)
The respiratory exchange ratio is defined as the ratio of carbon dioxide production to
oxygen consumption (VCO2/VO2) as measured with ventilatory gas analysis. It is a reflection of
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substrate metabolism and is used in exercise testing to quantify subject effort.38 In the resting
state, RER typically varies between 0.70 – 1.00 and increases with progressive exercise. A RER ≥
1.0 is associated with energy release from anaerobic metabolism and exercise‐induced
metabolic acidosis with resulting increases in VCO2. 79 Healthy controls achieve a respiratory
exchange ratio at peak exercise of between 1.10 and 1.20 or even higher, indicating that
anaerobic metabolism is occurring. 89 Such RER values are used to indicate maximal effort. 38
Assessment of maximal effort during exercise testing is important in heart failure,
particularly if the results are used for prognostication or to determine the appropriateness of
heart transplantation. A RER value equal to ≥ 1.0 is commonly used to describe adequate effort
and motivation in the CHF population. 90, 79 The International Society of Heart and Lung
Transplantation (ISHLT) define a maximal cardiopulmonary stress test as one with a RER > 1.05.
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It has also been described that a significant proportion, as many as 1 in 3 heart failure

patients are unable to reach such a maximal effort defined by the RER. 91 Furthermore, the
prognostic ability of common CPET variables (i.e. peak VO2, VE/VCO2 slope) decreases when the
RER is < 1.0. 89

Mechanical Circulatory Support (MCS) in Heart Failure
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As previously mentioned, heart transplant remains the definitive therapy for those with
end‐stage heart failure, although the number of potential recipients significantly outnumbers
the supply of donors.70 This has led to intense investigation of alternatives to heart transplant
and/or ways to prolong survival while awaiting transplant.92 Since the inception of the artificial‐
heart program at the National Institutes of Health (NIH) in 1964, various circulatory‐support
devices have been developed for short‐term use in patients with end‐stage heart failure.93 To
prevent the deaths of patients awaiting transplantation, many cardiac transplant centers have
developed programs to bridge patients to transplantation by means of mechanical circulatory
support devices.
Cooley and colleagues were the first to implant a total artificial heart (TAH) in a human
who could not be weaned from cardiopulmonary bypass following heart surgery. 94 The first
permanent TAH implanted, the Jarvik‐7 was performed by DeVries in 1982.94 In this well‐
publicized event, a patient by the name of Barney Clark was fully supported by the TAH for 112
days.94 The first successful bridge to cardiac transplantation with a mechanical device was
performed by Reemtsma and colleagues in 1978, which successfully supported patients with
intraaortic balloon pumps before transplantation. 95 In 1984 and early 1985, Hill, Starnes,
Copeland, and their associates performed successful bridging procedures using a pneumatic
paracorporeal ventricular assist device (VAD), an implantable electrical left ventricular assist
system, and a Symbion‐Jarvik 7 pneumatic total artificial heart (TAH). 96 Pennington and
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colleagues were the first to demonstrate efficacy and improved long‐term survival in transplant
recipients who were bridged with mechanical assist devices compared with optimal medical
therapy. 96 The 28th annual Adult Heart Transplant report from the International Society of
Heart and Lung Transplantation (ISHLT) reports the number of patients bridged to transplant
with mechanical circulatory support devices exceeded 30% for the first time in 2009. 70
The REMATCH trial demonstrated that the use of a left ventricular assist device in
patients with advanced heart failure resulted in a clinically meaningful survival benefit and an
improved quality of life. 97 Patients supported by a left‐ventricular assist device (LVAD) who
were not heart transplant candidates demonstrated a 48% reduction in mortality compared
with a medical‐therapy only group. 97
Current overall 1‐year/2‐year survival for LVAD patients is 79% & 66%, respectively. 10
This improved survival rate is approaching that of heart transplantation and has led some to
posit their utility on par with this current gold‐standard for advanced heart failure. 98
The INTERMACS database shows that 2,868 patients have received implantation of one
or more durable MCS devices between June 2006 and September 2010.10 The number of MCS
devices has increased from 100 total implants per year in 2006 to 668 total implants per year
through June of 2010, a 568% increase.10 The use of MCS devices as an alternative to heart
transplant for “destination‐therapy” compromises 15% of all implants. 10
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Types of Mechanical Circulatory Support (MCS) Devices
A vast array of MCS devices exist that differ based upon location of device, ventricle(s)
supported, indication of use, and type of blood flow. Intracorporeal MCS devices are those
which are implanted within the body and indicated for longer‐term support. Extracorporeal
devices are located outside the body and are used in short‐term situations for myocardial
recovery or cardiogenic shock. 99
The most recent INTERMACS data reveals that 87% of all adult MCS devices implanted
were left‐ventricular assist devices, 10% biventricular assist devices, and 3% total artificial heart
devices. 10 The left ventricle constitutes the majority of myocardial tissue thus the majority of
ventricular dysfunction is seen in this region. All implantable LVADs consist of an inflow
cannula connecting the left ventricle to the pump that then connects to an outflow cannula
carrying augmented blood flow to the aorta. 100 Right ventricular dysfunction alone is rare
although has been reported to be present following LVAD implant in up to 50% of instances. 101
Biventricular assist devices or BiVADs provide a parallel simultaneous mechanical circulatory
support to the left and right ventricles, pumping blood to the systemic and pulmonary systems.
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The total artificial heart (TAH) requires complete excision of the native ventricles and

anastomosis of the prosthetic ventricles to the atrial cuffs. 103 All current implanted MCS
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devices include a percutaneous exit for the driveline, a system controller, and an external
power source.104
Applications
MCS devices also differ based upon their intended use. Mechanical circulatory support
is utilized as a bridge to heart transplant, bridge to candidacy, destination therapy, and as
bridge to recovery or rescue therapy.10 The most common indication is as a bridge to transplant
in individuals accepted and listed for heart transplantation. 10
Bridge to decision or candidacy represents a growing indication for use wherein patients
receive a MCS device before a final decision has been rendered about heart transplantation.
Destination therapy represents those implanted with devices that are not eligible for heart
transplant because of advanced age or comorbidity. Advanced age (> 70years), renal
dysfunction, and high body mass index (BMI) are the leading three contraindications to
transplant. 10
Temporary or short‐term use of mechanical circulatory support is indicated when
recovery of native heart function is expected such as in acute myocarditis, postcardiotomy
shock, or following myocardial infarction complicated by cardiogenic shock. 100 105
MCS Flow‐Type
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Mechanical circulatory assist devices can be characterized into one of three categories
based upon mechanism of action. First generation or volume‐displacement pumps use
pneumatic (air‐driven) or electromagnetically actuated pusher plates to deform a membrane to
deliver pulsatile flow. A volume displacement pump consists of a chamber that passively fills
before a pusher plate compresses the chamber and ejects blood in pulsatile fashion through
the outflow conduit. 104 Pulsatile‐flow pump LVAD’s were the first type of MCS device used for
long‐term ventricular support and were shown to improve survival. 97 These devices however
were fraught with complications such as pump‐failure and very high risk of infection and
thromboembolic events.97 This improved survival, but unacceptably high complication rate led
to the development of second generation or axial‐flow pumps.
Axial‐flow pumps consist of an impellar (a rotor with helical blades) around a central
shaft that propels blood by drawing it into the inflow cannula and out through the outflow tract
along the axis of the impellar.104 These rotary pumps provide continuous‐flow and are non‐
pulsatile. They are associated with a significantly reduced incidence of thromboembolic events,
infection, smaller pump size, and significantly improved durability. 106 The first 2nd generation
continuous‐flow device approved for commercial use by the Food & Drug Administration (FDA)
was the HeartMate II left‐ventricular assist system© (Thoratec Corporation, Pleasanton, CA,
USA). 10 Continuous‐flow pumps compromise > 98% of all adult LVAD implants in the most
recent INTERMACS 6‐month reporting period (January through June 2010). 10 The HeartMate II
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continuous‐flow LVAD is the most commonly implanted MCS device on the market and the
best‐studied 2nd‐generation LVAD to date. 106
Third generation LVAD devices consist of a rotary pump which uses electromagnetic or
hydrodynamic forces to suspend an impellar within the housing to provide a contactless
surface. 104 It is anticipated that this type of pump will result in even further reduction of
thromboembolic events and reduce power consumption allowing even further portability.
However, there is limited information yet available on this generation of pumps although
clinical trials are underway. 104
The total artificial heart (TAH) is a pulsatile‐flow pump which uses a pneumatic driver
to power both ventricles. Copeland and colleagues at the University of Arizona implanted the
first TAH as a bridge to transplant in 1985.107 Currently, the SynCardia temporary TAH (formerly
known as the Cardiowest TAH) is the most effective bridge to transplant for those with
biventricular failure with a success rate of 79%. 12

Eligibility/ Selection Criteria
The selection criteria for use of a MCS device are similar to that of heart transplantation
in those who are being bridged to transplant. The use of destination therapy, however, has
expanded the number of those who qualify for MCS.
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Left‐ventricular Assist Device (LVAD)
The HeartMate XVE LVAS pulsatile‐flow pump is intended for use as a bridge to
transplantation in cardiac transplant candidates at risk of imminent death from non‐reversible
left ventricular failure. The HeartMate XVE is also indicated for use in patients with NYHA class
IV end‐stage left ventricular failure, who has received optimal medical therapy for at least 60 of
the last 90 days, who have a life expectancy of less than two years, and who are not candidates
for cardiac transplantation. It is intended for use both inside and outside the hospital. It is
contraindicated for patients whose body surface area is less than 1.5m2. 108
The HeartMate II continuous‐flow axial pump is also intended for use as a bridge to
transplantation in cardiac transplant candidates at risk of imminent death from non‐reversible
left ventricular failure. It is also indicated for use in patients with NYHA Class IIIB or IV end‐stage
left ventricular failure who have received optimal medical therapy for at least 45 of the last 60
days, and who are not candidates for cardiac transplantation. It is contraindicated in patients
who cannot tolerate or are allergic to anticoagulation therapy. 109
Total Artificial Heart
The SynCardia Total Artificial Heart – temporary© (Syncardia, Tucson, AZ) is intended
for use inside the hospital while patients await heart transplantation. The SynCardia total
artificial heart (TAH) is indicated for use as a bridge to transplantation in cardiac transplant
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candidates at risk of imminent risk of death from non‐reversible biventricular failure. 110 Other
indications included those with acute or chronic allograft failure, restrictive cardiomyopathy,
hypertrophic cardiomyopathy, extensive intracavitary thrombus and cardiomyopathy with
aortic root aneurysm. 24 The TAH system is also undergoing a clinical trial with a smaller
portable driver system, aptly named the SynCardia Freedom Driver, for use as a bridge to
transplantation in cardiac transplant candidates who are implanted with the TAH and are
clinically stable. The portable driver will allow hospital discharge. 111
The TAH System is contraindicated for use in patients who: 1) are not cardiac transplant
eligible, and 2) do not have sufficient space in the chest area vacated by the natural ventricles.
Generally, this includes patients who have body surface areas < 1.7m², or who have a distance
between the sternum and the 10th anterior vertebral body measured by computed
tomography imaging (CT scan) < 10 cm. Additionally, the TAH is contraindicated in patients
who cannot be adequately anti‐coagulated. 110 The Freedom Driver System is contraindicated
for use in TAH patients who are not clinically stable. 111

Physiology and Device Function of MCS
1st generation LVAD or pulsatile‐flow pump systems
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Currently, the Thoratec HeartMate extended Lead Vented Electric Left Ventricular Assist
System (XVE) is the only FDA‐approved commercially available 1st generation ventricular assist
device in the United States. It consists of an implanted blood pump, an external system
controller, and external power supply components. The blood pump, or LVAD, is a pusher‐plate
type device that is capable of producing a stroke volume of 83ml, generating approximately 10
liters of blood flow per minute, and a pump rate up to 120 bpm. 108
The pump consists of a rigid titanium housing divided in half by a flexible diaphragm.
One half functions as the blood chamber, while the opposite half serves as a chamber for the
electric motor. This motor chamber is connected to the external control and power
components via a percutaneous tube. Displacement of the diaphragm by rotation of the electric
motor results in pumping of the blood. 108
The XVE System Controller is a microprocessor‐based unit that initiates motor actuation,
monitors and reports on system function, and serves as the primary interface with the system.
The XVE System Controller provides two modes of operation, either Fixed Rate or Auto Rate.
The Auto Rate is programmed with OptiFill™ Software, which varies in response to physiologic
demand. LVAD function is adjusted by a switch panel located on the top of the system
controller, or via a separate system monitor. The system controller’s audio and visual alarms
alert users of potentially dangerous conditions. Alarms are sounded primarily if there are either
low flow or low stroke conditions or if battery charge levels are low. 108
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The XVE is routinely powered through the system controller by either a pair of wearable,
rechargeable batteries, or via connection to a dedicated power supply device. 108 Figure 2
provides an illustration of the HeartMate I XVE LVAD.

Figure 2: HeartMate I – XVE LVAD

2nd generation LVAD or continuous‐flow systems
The Thoratec HeartMate II LVAD is currently the only commercially available FDA‐
approved ventricular assist device for bridge to transplant and destination therapy in the
United States. It utilizes a rotary blood pump to generate flow and assist the left ventricle. It is
an axially configured device where the path of the entering and exiting flow stream is parallel to
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the pump’s axis. The device has only one moving part, the rotor assembly, which spins on
bearings located at either end of the assembly. The pump is driven by an external power source
via a percutaneous lead. Capable of generating blood flow up to 10 liters per minute, the LVAD
operates in parallel with the heart, such that either can supply blood to the aorta. Blood enters
the pump from the left ventricle via an inflow conduit. Blades on the spinning rotor move the
blood through the pump to an outflow graft and ultimately to the native circulation.109 It may
be surgically implanted beneath the diaphragm in either a preperitoneal or intra‐abdominal
location. An inflow conduit is inserted into the left ventricular apex of the heart. An outflow
graft is attached to the ascending aorta. 109 Figure 3 provides an illustration of the internal
components and the blood‐flow path within the HeartMate II LVAD.

Figure 3: Internal workings of HMII LVAD

A system controller controls the LVAD operation and serves as the primary user
interface. This controls motor power and speed, monitors, interprets, and responds to the
system, performs diagnostic monitoring, provides hazard and advisory alarms, records events in
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memory, and transfers data to a system monitor. 109 Device performance can be determined by
monitoring the pump speed, power, flow, and pulsatility index. 109
The LVAD operates at a fixed speed determined by the physician during a speed ramp
study. The fixed speed mode maintains the blood pump at a constant speed between 6,000
and 15,000 rpm. The fixed speed can be adjusted in increments of 200 rpm. 109
Pump power is a direct measurement of motor voltage and current. Changes in
pump speed, flow, or physiological demand can affect pump power. Gradual power increases
may signal a deposition or thrombus inside the pump. Depending on the speed, power values
greater than 10 to 12 watts (W) may also indicate the presence of a thrombus. 109
The pump flow and power generally retain a linear relationship at a given speed.
However, the power is directly measured by a system controller while the reported flow is
estimated based on power. Since the displayed flow is a calculated value, it becomes imprecise
at the low and high regions of the linear power‐flow relationship. 109
The increase in ventricular pressure during contraction causes an increase in pump flow
during cardiac systole. The magnitude of this flow pulse is measured and averaged over
intervals of 15 seconds to produce a pulsatility index (PI). The PI calculation represents cardiac
pulsatility, and values typically range from 1 to 10. In general, the magnitude of the PI value is
related to the amount of assistance provided by the LVAD. Higher values indicate more
ventricular filling and higher pulsatility (i.e. pump is providing less support to the left ventricle)
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and lower values indicate less ventricular filling and lower pulsatility (i.e. pump is providing
greater support, further unloading of the ventricle). PI values should be monitored and should
not vary significantly during resting conditions. Under otherwise stable conditions, a significant
drop in PI may indicate a decrease in circulating blood volume. 109

Figure 4: Thoratec HeartMate II LVAD

Total Artificial Heart (TAH)
The implantable Syncardia TAH consists of two artificial ventricles, each made of a semi‐
rigid polyurethane housing with four flexible polyurethane diaphragms separating the blood
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chamber from the air chamber. The diaphragms allow the artificial ventricle to fill and then
eject blood when compressed by air from the external console. Mechanical valves, mounted in
the inflow and outflow ports of each artificial ventricle, control the direction of blood flow. The
TAH weighs 160 grams, is composed of two pneumatically driven pumps, and has the ability to
deliver a cardiac output of up to 9.5 liters per minute at its maximal stroke volume of 70 ml. 110
The left artificial ventricle is connected via the left atrial inflow connector to the left
atrium, and via the aortic outflow cannula to the aorta. The right artificial ventricle is
connected via the right atrial inflow connector to the right atrium and via the pulmonary artery
outflow cannula to the pulmonary artery. Each artificial ventricle’s driveline conduit is tunneled
through the chest wall. The right and left artificial ventricle’s driveline conduits are attached to
seven‐foot pneumatic drivelines that connect to the back of the external console. 110 Figure 5
provides a visual depiction of the TAH location in comparison to the native human heart.
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Figure 5: Artificial Heart in comparison to Human Heart – courtesy of Syncardia Systems, Inc©.

The TAH has an external console (weighing 495 lbs. crated) aptly named “Big‐Blue” with
controllers permitting regulation of each of the ventricles. In addition to the controllers, the
console consists of several components essential to the functioning of the device, including a
vacuum pump, an alarm panel and two high‐pressure air tanks. The console includes a
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monitoring computer that provides noninvasive diagnostic and monitoring information to the
user. Device pump rate, dynamic stroke volumes, and calculated cardiac outputs are displayed
on a beat‐to‐beat basis. Drive pressure and flow waveforms, along with cardiac output trends
are provided. 110
The basic parameters of the device console that modulate cardiac output include drive
pressure, ejection rate, systolic ejection time and vacuum pressure during pump diastole. The
drive pressure regulators control the pressure of the air entering the ventricles and can be set
between 0 and 300 mmHg (with a typical range of 150 to 200 mmHg for the left ventricle and
55 to 90 mmHg for the right ventricle). The pump rate can be set between 25 and 199 beats
per minute (bpm) (typical range 90 to 130 bpm). The systolic duration, or the percent of the
cardiac cycle spent in systole, can be set at between 15% and 95% (typical range expected at
approximately 50%, but can range from 45% to 65%). The TAH features a vacuum that can
shorten ventricular filling time by drawing blood into the pumping chamber during pump
diastole. This vacuum pressure can be set to between 0 and 60 mm Hg (typical range 5 to 12
mm Hg). The aforementioned parameters are adjusted to maintain full ejection during systole
of both the right and left pump, and partial filling during diastole. The settings are adjustable
and optimized to provide clinically appropriate cardiac output and systemic blood pressures. 24,
110

Figure 6 provides an illustration of the TAH patient tethered to the “Big‐blue” driver.
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Figure 6: TAH with Big‐Blue Console

The TAH can also be powered by a portable console which is currently undergoing a
clinical trial for FDA approval. This portable console, called the SynCardia Freedom Driver and
weighs 14 lbs. is designed to improve patient portability and allow hospital discharge. All
Freedom Driver console parameters are fixed except for the beat rate which can be adjusted
manually by a physician. 111 Figure 7 illustrates the TAH patient with the significantly smaller
Freedom Driver console.
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Figure 7: TAH with SynCardia Freedom Driver Console

Exercise Physiology of MCS
In addition to prolonged survival, mechanical circulatory support offers heart failure
patients the opportunity for enhanced quality of life by improving end organ function and
activity tolerance. Advancements in device technology have led to increased portability,
patient acceptance, and the ability to participate in further activities of daily living. 10
Additionally, this allows the patient to undergo physical rehabilitation to further improve
functional capacity. Patients who may have previously been bedridden are now able to
participate in physical therapy and/or cardiac rehabilitation.20, 112, 113 To date most of the
literature regarding exercise capacity or therapy in the MCS patient has been based upon 1st
generation or pulsatile‐flow pump ventricular assist devices. In general, these studies support
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the safety and efficacy of exercise testing and intervention in the MCS patient.20 There is,
however, a distinct lack of studies examining the effects of exercise in MCS device patients. 20
1st generation LVAD or pulsatile‐flow pump systems
Although it is important to take into account native left ventricular function when
considering exercise physiology in the LVAD patient, the LVAD device contributes most of the
cardiac output. 114 Early work by Jaski et al. and Branch et al. with 1st generation LVADs
revealed that virtually all resting cardiac output was from LVAD support and its contribution to
exercise was variable. 115, 116 LVAD contribution to exercise cardiac output ranged from 66% to
93% with the remainder due to function of the left ventricle. These studies were some of the
first to show that the LVAD provides adequate cardiac output for most ADL level activities and
exercise participation. 114
Morrone et al. described the largest exercise experience of patients with 1st generation
LVAD’s.113 In a retrospective analysis of physical therapy intervention on patients surviving
LVAD implantation (n = 34), they found treadmill exercise was tolerated by 82% of patients and
could be initiated within 3 weeks of surgery. 113 Exercise performance peaked at 6 to 8 weeks
with patients able to perform 20 to 30 minutes at approximately 3.2 METs (estimated VO2 11.2
ml.kg‐1.min‐1. They reported maximal functional capacity was most influenced by medical
complications, and the only exercise related complications were a transient decrease in pump
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flow, which did not result in increased mortality/morbidity for the patients.113 These authors
posited that a delay in heart transplantation until peak performance of functional ability may
optimize post‐operative recovery.
In the EVADE trial (Experience with left Ventricular Assist Device with Exercise trial),
Jaski and colleagues found lower functional capacity determined by peak VO2 in post‐LVAD
patients compared with post‐heart transplant patients. 117 Eighteen patients implanted with an
intracoporeal LVAD underwent treadmill exercise testing with ventilatory gas analysis one to
three months after LVAD and then again one to three months following heart transplant (HTx).
Mean peak VO2 was 14.5 ml.kg‐1.min‐1 post‐LVAD and 17.5 ml.kg‐1.min‐1 post‐HTx. The
percentage of the predicted peak oxygen consumption based on gender, weight, and age was
39.5% post‐LVAD and 47.7% post‐HTx. The peak respiratory exchange ratio (RER) was similar
post‐LVAD and post‐HTx at 1.15, consistent with a good effort in both groups. After LVAD
implantation, peak total oxygen consumption correlated with peak LVAD rate and
output. 117
In contrast, de Jonge observed that peak VO2 12 weeks after LVAD implant did not differ
significantly from peak VO2 12 weeks after heart transplant (22.8 ml.kg‐1.min‐1 vs. 24.6 ml.kg‐
.min‐1 or 58% vs. 63% of predicted peak VO2). 118 They performed cardiopulmonary exercise
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testing (CPET) on 15 LVAD patients at 8 weeks and 12 weeks after LVAD implant and then again
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12 weeks after heart transplant and once more at 1 year after heart transplant. All patients
were started on an intensive post‐operative rehabilitation regimen as soon as they were able to
mobilize. Peak VO2 improved from 8 weeks to 12 weeks post‐LVAD and was commensurate
with a Weber functional class A status. Twelve weeks after LVAD the anaerobic threshold (AT)
was 14.4 ml.kg‐1.min‐1 and the VE/VCO2 slope was 37.2. They emphasized the timing of exercise
testing and the rehabilitation component as determinants of exercise capacity. 118
In another study of exercise capacity in patients with a pulsatile‐flow LVAD by Pruijsten
and colleagues, peak VO2 was 20.0 ml.kg‐1.min‐1 or 52% of predicted at a peak RER of 1.23, AT
was 13.8 ml.kg‐1.min‐1, VE/VCO2 = 35.9. 119 Approximately 50% (44 out of 84) of the eligible
patients underwent CPET at 12 weeks following LVAD implant. This exercise response was
similar to the findings in the de Jonge study.118
Mancini et al. described the bicycle‐ergometer exercise hemodynamic and metabolic
response of pulsatile‐flow LVAD patients (n=20) compared with ambulatory heart failure
patients awaiting heart transplant. Peak VO2 for the device patients was significantly greater
than the heart failure patients (16 vs.12.1 ml.kg‐1.min‐1). The VE/VCO2 at the anaerobic threshold
(ratio of 39) was similar for both groups. Fatigue was the primary limiting factor in the LVAD
group. Further peak exercise variables for the device patients were as follows: AT = 12.2 ml.kg‐
1

.min‐1, RER = 1.14, mean arterial pressure (MAP) = 96mmHg, peak heart rate (HR) = 148 bpm,
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peak cardiac output (C.O.) = 11.2 liters, cardiac index (C.I.) = 5.8, lactate = 5.0 mmol/L, peak
Borg RPE (0‐10 scale) = 5.9, peak Borg RPD (i.e. perceived dyspnea) = 4.8 on a 0 – 10 scale. 120
Simon and colleagues compared the exercise performance of patients with electric
LVAD (n=18), pneumatic‐driven LVAD (n=10), and pneumatic‐driven BiVAD (n=10). They found
percent predicted peak VO2 was significantly higher in the pneumatic‐driven LVAD vs. electric
LVAD (52.1% vs. 38.2%) with BiVAD having the lowest exercise tolerance (36.5%). 121 This
corresponded to oxygen consumption values of 15.7, 12.8, 11.8 ml.kg‐1.min‐1, respectively for
pneumatic LVAD, electric LVAD, and pneumatic BiVAD. Peak METs were 3.4 to 4.4 and VE/VCO2
slope values ranged from 41 – 43 between the groups. Peak mean arterial pressure (MAP) was
93 – 102 mmHg among the groups. Peak device outputs ranged from 6.5 to 7.9 liters per
minute. Peak RER was 1.17 ‐ 1.26. 121
It is notable that although pulsatile‐flow LVAD and the heart function in parallel, native
heart rate and pulsatile‐flow LVAD pump rate are not simultaneous.114 Both increase in a linear
fashion with exercise although independent of one another. The pulsatile‐flow LVAD pump rate
is fixed or based on physiologic demand wherein it operates in a fill‐to‐empty mode. 114
Laoutaris et al. looked at the benefits of physical training on exercise capacity,
inspiratory muscle function, and quality of life in patients with a ventricular assist device long‐
term post‐implantation. 112 In this study, 15 patients, approximately 6.3 months after implant
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underwent bicycle‐ergometer CPET, 6MWT, and inspiratory muscle testing. This group
consisted of a combination of intracorporeal continuous‐flow rotary pump LVAD (n=2),
extracorporeal pulsatile‐flow LVAD (n=6), and extracorporeal pulsatile‐flow BiVAD (n=7).
Subjects were assigned to a training group or control in 2:1 fashion. The training group
significantly increased peak VO2 (16.8 to 19.3 ml.kg‐1.min‐1) at a mean RER of 1.13 ‐ 1.2,
increased VAT (12 to 15.2 ml.kg‐1.min‐1), increased 6MWD (462 to 527 meters), and lowered
VE/VCO2 slope (40 to 35.9). 112
Alternatively, Humphrey et al. found that exercise‐training in an LVAD group did not
result in substantial increases in peak oxygen consumption as much as submaximal responses,
such as the ventilatory anaerobic threshold. 20 This is, however, not surprising given that peak
oxygen consumption via the Fick equation is largely determined by peak cardiac output which is
mostly influenced by the LVAD device that has fixed upper limits.
In summary, a review of the above studies reveals that exercise capacity is generally
improved with ventricular assist device support compared with medically managed end‐stage
heart failure patients. However, it is generally lower compared with post‐heart transplant
patients. Exercise capacity in the MCS patient ranges from 14 to 24 ml.kg‐1.min‐1 (4 – 6.9 METs)
for peak VO2 although remains at about 40‐60% of predicted compared with normal. The
observed anaerobic threshold values seem to range from 12 to 14 ml.kg‐1.min‐1 or 3.4 – 4.0
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METs. It also appears the VE/VCO2 slope remains high and above normal after device implant
with values ranging from 36 to 43 units. The high RER values (i.e. >1.1) from these studies also
support that sufficient effort was put forth during testing indicative of a maximal effort. It is
also noted that overall the sample size of available exercise studies is small (i.e. ~ 10 – 34
patients). As expected, exercise training also seems to influence the exercise response.
Currently, there do not appear to be any studies in the literature describing the OUES, EOV, or
PetCO2 response to exercise in MCS device patients.
2nd generation LVAD or continuous‐flow systems
Haft et al. demonstrated exercise performance was similar in those with a continuous‐
flow pump LVAD compared with pulsatile‐flow pump devices. 122 Thirty‐four patients with a
volume‐displacement HeartMate XVE (n=16) or HeartMate II (HMII) continuous‐flow rotary
pump (n=18) underwent right‐heart catheterization, echocardiography, and CPET 3‐months
post‐operatively. Exercise capacity was similar (VO2 for XVE = 47% of predicted vs. 49% for
HMII) between the groups. The results indicated both types of LVAD pumps provided
equivalent degrees of hemodynamic support and exercise capacity. Additional peak exercise
response variables compared between the groups were as follows: Peak VO2 ‐XVE = 15.4 vs.
HMII = 15.6 ml.kg‐1.min‐1, METs‐XVE = 4.4 vs. HMII = 4.3, RER‐XVE = 1.13 vs. HMII = 1.11, peak
HR‐XVE = 131 bpm vs. HMII = 124 bpm. 122

57

This similar finding of exercise capacity is important as previous studies have suggested
axial‐flow rotary pumps provide similar degrees of pressure unloading but less volume
unloading of the left‐ventricle (LV) as compared with pulsatile‐flow pumps. Thus axial‐flow
rotary pumps at a fixed rotor speed may not appropriately adjust to the increased LV preload
during exercise leading to impaired exercise performance. 123 The Haft study did show a major
difference in the degree of LV volume unloading between device types although equivalent
exercise performance. 122
Important considerations when interpreting the exercise response of the continuous or
pulseless‐flow LVAD are the measurement of cardiac output and arterial blood pressure.
Cardiac output in the pulseless‐flow LVAD is only an estimation of pump flow based upon
power consumption. 124 Lack of a direct assessment of cardiac output during exercise does not
allow determination of the contribution of native ventricular function. Jaski et al.
demonstrated, albeit with a pulsatile‐flow LVAD, that resting cardiac output was almost solely
due to LVAD support, but during exercise aortic ejection was apparent and total systemic
cardiac output exceeded the LVAD support. 116
Brassard and colleagues performed a study wherein they invasively determined cardiac
output, leg blood flow, cerebral perfusion and whether an increase in LVAD pump speed with
work rate would increase organ blood flow. 125 Eight patients with a HeartMate II continuous‐
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flow LVAD underwent incremental cycle ergometer exercise testing with a progressive protocol
of 30‐watt stages of 2‐minutes using a modified semi‐supine ergometer at a pace of 60 rpm.
Exercise time was approximately 12 minutes and subjects were able to reach peak workloads of
150 – 180 watts. They found significant increases in cardiac output to maximal exercise at both
a constant pump speed of 9775 rpm (7.0 to 13.6 L/min) and an increasing pump speed of 400
rpm per stage (6.0 to 12.1 L/min). Both groups exhibited poor cerebral blood flow although this
was augmented with increasing pump speed. 125
Unfortunately, this group did not report on ventilatory gas‐analysis measurements (i.e.
peak VO2) and only very limited information regarding the LVAD device estimated function from
the system controller. Measurement of peak VO2 and device estimated function would have
allowed determination of device and native LV contribution to exercise cardiac output.
Additionally, this could have led to potential correlations between device flow estimates and
exercise capacity.
The major hemodynamic effects of a continuous‐flow LVAD are increases in diastolic
pressure and flow. Because these devices pump continuously throughout the entire cardiac
cycle, aortic flow is also present during diastole when normal pulsatile flow is absent. When the
pump speed of a continuous‐flow LVAD is increased, the diastolic pressure rises, the systolic
pressure remains fairly constant, and the pulse pressure (systolic pressure minus diastolic
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pressure) is greatly reduced. 126 Owing to the reduced pulse pressure during continuous‐flow
LVAD support, it is often difficult to palpate a pulse and measure blood pressure accurately by
the usual ausculatory or automated methods. When listening with a manual blood pressure
cuff, the start of the Korotkoff sound is a pressure value that is estimated to be in the range of
the systolic and diastolic pressures. The arterial blood pressure is most reliably assessed using
Doppler and a sphygmomanometer. Pressure values obtained using the Doppler method may
be measured at any point during the cardiac cycle and should not necessarily be considered the
actual systolic, diastolic, or mean pressure values. 127
Total Artificial Heart (TAH)
The effectiveness of the TAH as a bridge to transplant has made it a viable option for
those with end‐stage biventricular heart failure. The demonstrated improvement in mortality
and its increasing usage necessitates a shift in focus to quality of life in the TAH patient
including functional ability. The assessment of functional ability is further called for considering
a current FDA‐trial investigating the efficacy of a portable TAH device allowing reintegration
into the community. As seen with other MCS devices, functional ability is largely influenced by
the limits of the device. This is certainly the case in the TAH patient wherein there is no native
heart to contribute cardiac output during exercise.
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In 1989 Everett 1st described the effect of graded exercise on cardiac output of the
Jarvik‐7‐70 total artificial heart in a human. 21 The Jarvik‐7‐70 TAH was an earlier version of the
current SynCardia TAH. Using a cycle ergometer with 18‐watts (est. METs ~2.7) resistance the
TAH patient could exercise with an auto‐regulated cardiac output and no deleterious effects. 21
Exercise was started on the 35th post‐operative day and performed without adjusting fixed
device parameters. Increasing the work of exercise produced an increased cardiac output
through an augmented exercise stroke volume facilitated by changes in venous return. 21
Later, Copeland and colleagues described the early functional status in a series of
SynCardia TAH patients awaiting heart transplant. They reported 75% of patients were out of
bed within one week of implant and were walking greater than 100 feet within two weeks. 12
Nicholson et al. describe a detailed physical therapy intervention in the TAH patient. 22
This was a single‐patient case study during which they chronicled a 12‐week progressive
exercise regimen wherein the patient safely progressed to tolerating 46 minutes of treadmill
ambulation at 1.4 mph/0% grade or approximately 2.1 metabolic equivalents (METs). Physical
therapy was initiated on the 7th post‐operative day and treadmill training was initiated on the
42nd post‐operative day (i.e. 6‐weeks). The patient was successfully transplanted after 83 days
on the artificial heart.22 This single patient case study was the first to demonstrate the safety of
a progressive exercise regimen in the TAH patient.
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Bellotto et al. utilized the fixed central component in the TAH patient to examine the
peripheral adaptations to exercise training.23 They reported the case of a single TAH patient
who underwent a comprehensive exercise training program and was evaluated by repeated
cardiopulmonary exercise tests. The TAH patient experienced a 24% increase in peak VO2 and
an improvement in recovery kinetics during the training period of 29 months. The patient, a
53year‐old male (BMI = 25 kg/m2, Hemoglobin = 10.1g/dL) underwent 4 repeated CPET’s
approximately 6 months apart using a cycle‐ergometer and a progressive work rate protocol of
5‐watts per minute. Peak VO2 improved from a baseline of 13.9 ml.kg‐1.min‐1 to a highest value
of 17.3 ml.kg‐1.min‐1. The AT improved from 9.8 to 10.6 ml.kg‐1.min‐1. Average resting blood
pressure was 116/83mmHg and changed to 121/79mmHg at peak exercise. Average RER and
VE/VCO2 slope was 1.2 and 27.8, respectively. The cardiac output response to exercise was
approximately 1.7 liters per minute. Comparison of the CPET results shows the peak VO2
significantly increased despite similar device flow, hemoglobin, and carbon dioxide output. This
suggests a greater extraction of oxygen from the blood perfusing the muscles reflecting a
peripheral adaptation.23 This appears to be the only study in the literature describing
ventilatory gas‐analysis variables during exercise in the TAH patient.
Most recently, Kohli and colleagues retrospectively reviewed the exercise performance
of TAH patients (n=37) undergoing inpatient rehabilitation and compared blood pressure
response and submaximal exercise capacity with a HeartMate II LVAD group. 24 Physical
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therapy was initiated at a median 5th post‐operative day and treadmill exercise was initiated on
the 19th post‐operative day. TAH patients were able to safely tolerate progressive aerobic
exercise training over time. Over eight weeks, patients were able to significantly improve
exercise duration (up to 26 + 15 minutes) and intensity (up to 2.3 + 0.5 METs). Compared with
LVADs, TAH patients demonstrated a blunted blood pressure response to exercise.24 To date
this is the most comprehensive series evaluating the exercise response in the TAH patient.
Summary/ Conclusions
A diagnosis of heart failure carries with it an ominous prognosis. A number of
pharmacologic and therapeutic regimens have proven efficacious at ameliorating its
pathological process. For patients with advanced heart failure, heart transplantation remains
the most effective treatment. Unfortunately, there is a long‐term trend wherein the number of
eligible recipients significantly outweighs the number of available donors. Mechanical
circulatory support devices have proven to be an effective short and long‐term option to reduce
mortality in those who await heart transplant. These devices also confer improvements in
quality of life, reduce symptoms, and improve functional status in patients with end‐stage heart
failure leading to their additional use as destination‐therapy in individuals who do not qualify
for heart transplant.
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For patients with severe biventricular heart failure the total artificial heart (TAH) has
become a viable option to bridge patients until transplant becomes available. Its abrupt
restoration of blood flow allows rehabilitation and organ recovery to take place promoting
optimization of the candidate before transplant. The demonstrated safety, increased usage,
growing transplant wait‐list times, and an ongoing clinical trial with a portable‐driver
necessitate further study of the TAH response to physical activity. This will allow determination
of device safety, elucidate the role of exercise training, potentially provide advice on
optimization of device settings, and provide guidelines on the functional limits of the device.
Presently, there is a dearth of information available in the literature on the exercise response of
the MCS device patient particularly the TAH patient. What is available demonstrates a
significantly reduced but functional exercise capacity. No studies to date have analyzed the
prognostic potential of the exercise response in this population. The goal of this study will be
to advance the knowledge base of the exercise response in this growing patient population.
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A Comparison of Maximal Exercise Responses among Patients with a Total Artificial Heart, a
Left Ventricular Assist Device, or Advanced Heart Failure
ABSTRACT
Objectives. The purpose of this study was to evaluate graded exercise responses to treadmill exercise in
patients with a total artificial heat (TAH). Additionally, this study sought to compare the exercise
response in TAH patients to both advanced heart failure (HF) patients on medical management only and
HeartMate II (HMII) LVAD patients. Background. For patients with biventricular heart failure the total
artificial heart (TAH) is a viable option to bridge patients until transplant becomes available. Its
demonstrated improvement in mortality and increasing usage necessitates a shift in focus to quality of
life in the TAH patient including functional ability. The evaluation of cardiorespiratory responses to
graded exercise provides an objective measure of functional ability. There is very limited information in
the literature on the exercise response of the mechanical circulatory support (MCS) device patient,
particularly the TAH patient. Methods. A study was conducted on previously gathered data of MCS
patients who underwent symptom‐limited cardiopulmonary exercise testing (CPET) following device
implant of either TAH or HMII. ANOVA was performed to compare differences between the two device
groups and HF patients listed for heart transplant. Results. Fourteen TAH patients underwent CPET (9
male, 5 female) with peak oxygen consumption (VO2) of 0.926 + .168 L∙min, 36 + 8% % predicted, 11.0 +
2.3 ml.kg.min or 3.1 + 0.7 METs. Ventilatory anaerobic threshold (VAT) was 0.706 + .181 L∙min. Peak
VO2, % pred. VO2 and VAT were significantly lower in the TAH compared with HMII and advanced HF (p
= 0.0012, p = 0.0106, p = 0.0009, respectively). Peak RER was significantly higher (p = <.0001) and OUES
was significantly lower (p = 0.0004) in the TAH. Conclusion. Exercise capacity is significantly reduced in
the TAH patient below that observed in HMII LVAD and advanced HF patients. This provides a baseline
for expected functional status and has implications on the ADL tolerance of these individuals. The next
step is to develop strategies to ameliorate this continued exercise intolerance.
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Abbreviations
MCS = Mechanical circulatory support

CPET = Cardiopulmonary exercise test

M=Male

ARB = Angiotensin II receptor blocker

F = Female

CCB = Calcium channel blocker

C = Caucasian

HDZN/ISDN = Hydralazine/ Isosorbide dinitrate

AA = African‐American

VO2 = oxygen uptake

O = Other

METs = Metabolic equivalent

NICM = Non‐ischemic cardiomyopathy

VAT = Ventilatory anaerobic threshold

ICM = Ischemic cardiomyopathy

RER = Respiratory exchange ratio

CHD = Congenital heart disease

OUES = Oxygen uptake efficiency slope

BMI = Body mass index

VE = Minute ventilation

Hgb = Hemoglobin

VCO2 = Carbon dioxide output

LVEF = Left‐ventricular ejection fraction
BTT = Bridge to transplant

EOV = Exercise oscillatory ventilation
PetCO2 = Partial pressure end‐tidal carbon
dioxide

BTD = Bridge to decision

TAH = Total artificial heart

DT = Destination therapy

ESHF = Advanced heart failure

DM = Diabetes
PVD = Peripheral vascular disease

HMII = HeartMate II LVAD
RHR = Resting heart rate

COPD = Chronic obstructive pulmonary disease

MAP = Mean arterial pressure

Afib = Atrial fibrillation
AICD = Automatic internal cardioverter
defibrillator

RPE = Rating of perceived exertion

B‐blocker = beta‐blocker

DOE = Dyspnea on exertion

ACE‐I = ACE Inhibitor

LE = Lower extremity

RPD = Rating of perceived dyspnea

Introduction
Heart failure, which is a syndrome that includes circulatory congestion and/or
inadequate tissue perfusion, can be caused by any type of condition that damages the heart
and typically leads to debilitating symptoms of dyspnea, fatigue, and exercise intolerance. It
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carries attributable risks, increasing incidence, an ominous prognosis, complex
pathophysiology, and can be a challenge to manage.1 The American Heart Association
estimates that there are 5.7 million Americans living with heart failure and 600,000 new cases
are diagnosed annually. 2 Lifetime risk of heart failure development is 1 in 5 for both men and
women, and hypertension is associated with 75% of all heart failure cases. 3, 4 Furthermore, the
incidence is highest among African‐Americans and it increases with advancing age. 5, 4 Risk
factors for the development of heart failure include coronary artery disease, hypertension,
cardiomyopathy, myocardial infarction (MI), obesity, diabetes, dyslipidemia, valvular heart
disease, renal insufficiency, sleep‐disordered breathing, and tachycardia. 1, 6 Antecedent MI and
hypertension are the most attributable risk factors. 3, 7 Approximately 50% of those diagnosed
with heart failure will die within 5 years and it carries a mortality risk that is four times that of
the general population of like age.7, 8 Lastly, heart failure is the most common hospital
discharge diagnosis and consumes more Medicare dollars than any other diagnosis.2, 7
Advanced heart failure therapies are available for patients with end‐stage disease who
are refractory to conventional medical management. This includes the use of inotropic agents,
heart transplantation, and mechanical circulatory support (MCS) devices.1 Heart
transplantation remains the definitive therapy for those with refractory end‐stage heart
failure.9 Unfortunately, the demand for heart transplants continues to significantly exceed the
supply of donor hearts.9 This has led to the increasing use of mechanical circulatory support
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devices to keep patients alive until heart transplant.10 To date, the majority of MCS devices
implanted are left‐ventricular assist devices (LVAD) which unload the native heart’s left
ventricle and improve survival and quality of life.10 However, there is a subset of patients with
advanced heart failure that are not appropriate candidates for LVAD therapy due to right‐sided
heart failure or biventricular failure.11 For these patients, the SynCardia Total Artificial Heart
(TAH) is the most effective treatment therapy as a bridge to heart transplant.12 The TAH
consists of two pneumatically driven pumps that orthotopically replace the failing hearts native
ventricles.11
Typically, clinical evaluation of the heart failure patient includes identification of causes,
description of symptoms, evaluation of cardiac structure, and quantification of functional
status.13 Patients are stratified according to heart failure risk, presence of cardiac structural
changes, functional status, and presence of symptoms.13 This allows determination of
prognosis and guides management. In heart failure, cardiopulmonary exercise testing (CPET)
has proven to be a reliable tool to guide therapy, estimate prognosis, and evaluate patients for
heart transplant.14 Quantification of the exercise response in heart failure is valuable because
of its ability to determine prognosis and provide insight into the pathophysiological processes
of the disease state.15, 16 In healthy individuals, the ability to perform dynamic activities is
largely determined by the hearts ability to appropriately increase cardiac output to provide
adequate blood flow and oxygen to working muscles and organs.14 In heart failure, a reduced
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cardiac output along with pulmonary congestion and deconditioning lead to impairment in the
ability to perform exercise17 therefore exercise intolerance is a hallmark symptom of heart
failure along with pulmonary congestion. The relationship between exercise performance and
heart failure severity has led to the use of exercise testing in the evaluation and management of
heart failure patients.
Due to its ability to stratify risk and accurately measure exercise capacity, CPET is
considered a core assessment of the heart failure patient.18 CPET variables have been shown to
correlate with cardiac function, pulmonary hemodynamics, and neurohormonal status.18
Standard CPET variables assessed in heart failure include peak oxygen consumption, ventilatory
anaerobic threshold, ventilatory efficiency slope, oxygen uptake efficiency slope, partial
pressure of end‐tidal carbon dioxide, presence of an exercise oscillatory breathing pattern, and
respiratory exchange ratio.19
Most of the available literature describing exercise in the MCS patient has been based
upon 1st generation or pulsatile‐flow left ventricular assist devices. There is, however, a distinct
lack of studies examining the effects of exercise in MCS device patients20 particularly the newer
continuous‐flow LVAD devices. In regards to the exercise response of the TAH patient there is
an even further paucity of information with very few studies available describing the functional
status of the TAH patient.12, 21, 22‐24 Therefore, the purpose of this study was to evaluate the
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cardiorespiratory responses to graded exercise in the TAH patient. Additionally, we sought to
compare those responses to responses obtained from HeartMate II LVAD patients and non‐MCS
device patients with advanced heart failure who had been evaluated and accepted for heart
transplantation. We hypothesized that exercise capacity, specifically the peak oxygen uptake,
will be significantly reduced in heart failure patients after TAH implant compared with
HeartMate II LVAD patients and patients with advanced heart failure un‐supported by MCS
device. Additionally, we hypothesized that an abnormally elevated ventilatory response to
exercise exists in the TAH patient due to the early onset of acidosis. This will result in an
increased ventilatory efficiency slope and a concomitant reduction in the oxygen uptake
efficiency slope in the TAH patient compared with HeartMate II LVAD patients and patients with
advanced heart failure un‐supported by MCS device. The initial characterization of this exercise
response along with comparisons to other HF populations will provide insight into the
functional limitations of the TAH patient and possible mechanisms for their exercise
intolerance.
Methodology
This study was conducted on previously gathered data of cardiopulmonary exercise tests
(CPET) that were performed on patients who received a mechanical circulatory support (MCS)
device at Virginia Commonwealth University Medical Center (VCUMC) from June 2010 through
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December 2011. Additionally, the CPET results of patients with MCS devices were compared
with advanced heart failure (ESHF) patients without a MCS device who underwent evaluation
and subsequent listing for heart transplant within the VCU Medical Center Advanced Heart
Failure program during the same time period. Institutional review board approval was granted
prior to data analysis. All patient information was de‐identified to maintain privacy and
confidentiality. All exercise tests were clinically‐mandated by an attending cardiologist within
the VCU Medical Center Advanced Heart Failure program. Rationale for testing was to
determine exercise capacity, to develop a cardiac rehabilitation exercise prescription, to
establish activity guidelines, to stratify risk, and to assess device function during exercise. All
patients were informed of the exercise test rationale, protocol, and associated risks prior to
consent being obtained.
Patient Population
The study was comprised of patients with an established diagnosis of heart failure who
were being followed by the VCU Medical Center Advanced Heart Failure program. Patients
were separated into 3 groups: 1) Thoratec© HeartMate II continuous‐flow left‐ventricular assist
device (HMII), 2) SynCardia© total artificial heart (TAH), and 3) advanced heart failure (ESHF)
without an MCS device who were listed for heart transplant.

71

Twenty‐two patients underwent TAH implant during June 2010 through December
2011. Out of the TAH group 14 patients (64%) were able to undergo CPET. The remaining 8
patients did not undergo post‐operative CPET for the following reasons: 4 patients underwent
heart transplant before CPET, 3 patients were medically unstable, and 1 patient expired.
Thirty‐four patients underwent HeartMate II LVAD implant from June 2010 through June
2011. Nineteen of 34 HMII patients (56%) underwent post‐operative CPET. Reasons for not
completing CPET for the remaining 15 patients included: 8 were not medically stable or a
physician deemed the patient too debilitated to tolerate treadmill exercise testing, 4 were lost
to follow‐up, and 3 expired. Five of the original nineteen HMII CPET’s were performed with a
different testing modality (i.e. bicycle ergometry) and were not comparable to the other groups
thus were excluded from the final analysis. Fourteen HMII patients who underwent treadmill
CPET were included in the final analysis.
The advanced heart failure (ESHF) patients were a convenience sample of those who
underwent treadmill CPET as part of their heart transplant evaluation and were subsequently
listed for heart transplant during the same time period at VCU Medical Center. Seventeen
patients with advanced heart failure who underwent symptom‐limited treadmill CPET and listed
for heart transplant by the VCUMC Heart Transplant committee were included in the final
analysis.
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The following clinical characteristics were examined in all groups to describe the sample:
1) Age (years), 2) Gender (Male or Female), 3) Race (Caucasian, African‐American, Other), 4) HF
etiology (Non‐ischemic cardiomyopathy (NICM), Ischemic cardiomyopathy (ICM), Congenital
Heart disease (CHD)), 5) Body mass index (BMI) in kg/m2, 6) Hemoglobin concentration (Hgb)
expressed as milligrams per deciliter (mg/dL). Additionally, left‐ventricular ejection fraction
(LVEF %) was obtained in the ESHF and HMII groups. Indication for MCS device was determined
in the TAH and HMII groups as either: 1) Bridge to transplant (BTT), 2) Destination therapy (DT),
3) Bridge to decision (BTD). Post‐operative day of CPET was also obtained in the MCS device
groups and was defined as the number of days between device implant and date of CPET.
Presence of comorbidities that might affect the exercise response was examined across
the three groups. Comorbidities of interest included diabetes (DM), peripheral vascular disease
(PVD), smoking status within last 6 months, chronic obstructive lung disease (COPD), electronic
cardiac pacemaker at the time of CPET, presence of atrial fibrillation at the time of CPET, and
sedentary lifestyle defined as not meeting American College of Sports Medicine physical activity
guidelines for adults at the time of CPET.
Standard heart failure therapies were also examined including automatic internal
cardioverter defibrillator (AICD) use and pharmacological therapies of Beta‐blocker, ACE
inhibitor (ACE‐I), Angiotensin II receptor antagonist (ARB), Aldosterone antagonist, Calcium
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channel blockers (CCB), Hydralazine/ Isosorbide dinitrate (HDZN/ISDN), other cardiovascular
vasoreactive medications.
Testing Protocol
Contraindications to exercise testing were based on established American College of
Cardiology/ American Heart Association Guidelines for exercise testing.25 MCS device patients
were considered appropriate for CPET once they were deemed medically stable by the
attending physician and felt to be sufficiently ambulatory per cardiopulmonary rehabilitation
staff. Sufficient ambulatory status was arbitrarily defined as able to tolerate motorized
treadmill walking of at least 1.0 mph for at least 5 minutes duration without a rest break. All
tests were symptom‐limited in nature and physician supervised. Testing was administered by a
qualified clinical exercise physiologist.
The treadmill protocol utilized was a conservative incremental ramping protocol
wherein the speed and grade increased by approximately 0.6 estimated metabolic equivalents
(est. VO2 ~2 ml.kg‐1.min‐1) every 30 seconds. This treadmill protocol has been previously
described and utilized in a heart failure population.26 Ventilatory gas‐analysis was performed
using a VMax Encore metabolic cart (Carefusion, Yorba Linda, CA) with a standard mouthpiece
and nose clip. The metabolic cart was calibrated for volume and gas‐concentration prior to
every test. Testing was not performed without successful calibration. Ventilatory gas‐analysis
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measurements were obtained for at least 3 minutes in the seated position before the start of
exercise, continuously throughout exercise and 2 minutes into the recovery period. Blood
pressure was monitored with a Tango+ exercise blood pressure system (Suntech Medical,
Morrisville, NC) in the ESHF and TAH groups. HMII patient blood pressure was monitored via
aneroid sphygmomanometer and Huntleigh ‐ 8MegaHertz Doppler probe (Arjohuntleigh, USA).
Blood pressure obtained with this method was a single reading and defined as the mean
arterial pressure (MAP). Sphygmomanometer blood pressure cuff and Doppler probe is the
recommended way to monitor blood pressure in this patient population.27 Blood pressure
measurements were monitored during seated rest, standing, every 2 minutes during exercise,
and every minute following exercise up to 6 minutes into recovery and/or until the patient was
stable. Twelve‐lead electrocardiography was performed continuously in the ESHF and HMII
patients with standard Mason‐Likar exercise lead placement.
The TAH hospital driver (“Big‐blue”) function was assessed through a CPU monitor
attached to the pneumatic driver displaying calculations of left and right fill volume and cardiac
output. The CPU monitor also displays waveforms indicating ejection pressure and chamber
filling with each cardiac cycle. The TAH Freedom Driver system console displays calculations of
left fill volume and left cardiac output in addition to the set device pump rate. Device
parameters were recorded pre, during exercise every two minutes and during the recovery
period. All device settings remained fixed throughout testing.
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HMII function was assessed through a display console that reported estimated device
flow, speed, pulsatility index, and pump power. The HMII speed was left unchanged during
testing. Device parameters were recorded pre, during exercise every two minutes, and during
the recovery period.
Exercise Variables Assessed
The following CPET exercise variables were compared between the three groups: peak
oxygen consumption (peak VO2), anaerobic threshold (VAT), peak respiratory exchange ratio
(RER), ventilatory efficiency slope (VE/VCO2 slope), oxygen uptake efficiency slope (OUES),
presence of exercise oscillatory breathing pattern (EOV), and partial pressure end‐tidal CO2
(PetCO2) at rest, VAT, and peak exercise.


Peak oxygen consumption (peak VO2) is considered the gold‐standard measurement of
exercise capacity. It is also the most frequently described exercise variable in the heart
failure literature.28 Moreover, there is a high test‐retest reliability and reproducibility of
this measurement in heart failure patients.29, 30 In normal healthy individuals exercise
capacity (i.e. aerobic exercise capacity) can be determined from work rate due to the
close linear relationship between work rate and oxygen consumption.31 However, in HF
oxygen uptake kinetics with exercise are altered.32 Therefore, direct measurement of
exercise capacity is recommended over estimates based upon exercise time or workload
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in this population.25 Peak VO2 was defined as the highest 30 second interval average
obtained from breath by breath measurements of VO2 during peak exercise. It was
expressed and analyzed with both absolute (Liters∙minute) and relative to bodyweight
(mLO2∙kg−1∙min−1). Additionally, it was expressed and analyzed by percent of predicted
(% predicted) normal values using the reference values of Wasserman et al.33


The ventilatory anaerobic threshold (VAT) is a submaximal indicator of exercise capacity.
In normal healthy individuals it is highly reproducible and identifiable.31 This measure
has also been found to be reproducible in HF patients.30 In heart failure, VAT is often
more difficult to ascertain partly due to the abnormal ventilatory pattern often
observed in this population.34 Anaerobic threshold was defined using the ventilatory
equivalents method.35 This consists of using the VO2 value observed when the minute
ventilation (VE) to oxygen consumption (VE/ VO2) ratio reaches its nadir and starts to
subsequently increase without a simultaneous increase in the minute ventilation to
carbon dioxide output (VE/VCO2) ratio. It was expressed and analyzed as both absolute
(Liters∙minute) and relative to bodyweight (mLO2∙kg−1∙min−1). Additionally, it was
expressed and analyzed by percent of predicted (% predicted) normal peak VO2 values
using the reference values of Wasserman et al.33
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The peak respiratory exchange ratio (RER) is defined as the ratio of VCO2/VO2
corresponding to the peak VO2 at the end of exercise. This is used to quantify subject
effort during exercise testing. A peak RER of 1.10 or greater is considered a universal
indicator of maximal exercise effort independent of patient characteristics such as age,
sex, fitness, and disease state.36 Peak RER was defined as the highest 30 second interval
average obtained during exercise.



The slope of the relationship between VE and VCO2 describes the ventilatory efficiency
during effort, showing the amount of air that must be ventilated to eliminate 1 liter of
carbon dioxide. The VE/VCO2 slope is defined as the linear regression value (y = mx + b
where m = slope) of the relationship between minute ventilation and carbon dioxide
production during exercise. Data analysis was based upon 10‐second interval averages
for minute ventilation and carbon dioxide production throughout the entire exercise
period.



The oxygen uptake efficiency slope (OUES) represents the rate of increase of VO2 in
response to a given VE during incremental exercise, indicating how effectively oxygen is
extracted and utilized. It is a reliable and reproducible measure of exercise ventilatory
efficiency and highly correlates to peak VO2.37, 38 The OUES is determined from the linear
relation of VO2 (y‐axis) versus the logarithm transformation of VE (x‐axis) during
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exercise, that is, VO2 = a log10 VE + b, where ‘a’ is the OUES and ‘b’ is the intercept.
Data analysis was based upon 10‐second interval averages for minute ventilation
(Liters∙minute) and absolute oxygen uptake (Liters∙minute) throughout the entire
exercise period.


Exercise oscillatory ventilation (EOV) was identified based upon the definition used by
Corra et al.39 Presence of EOV is indicated by cyclic fluctuations in pulmonary minute
ventilation at rest that persist during effort lasting ≥ 60% of the exercise duration, with
an amplitude ≥ 15% of the average resting value.



Partial pressure of end‐tidal carbon dioxide (PetCO2) is the measurement of carbon
dioxide present in exhaled air and is expressed in mmHg. It is a reliable and noninvasive
estimate of the partial pressure of arterial carbon dioxide (PaCO2).40 It correlates well
with peak VO2, VE/VCO2, cardiac output, and pulmonary function.33, 40, 41 Lower values at
rest and during exercise are observed in heart failure compared with normal individuals
and measurements of PetCO2 correlate with cardiac output and severity of disease.41, 42
Resting measurements were based on the average value of at least two minutes of pre‐
exercise resting data. Exercise measurements were expressed as the PetCO2 observed
at the anaerobic threshold or the highest value obtained if anaerobic threshold is
undetectable.19, 42, 33
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Statistical Analysis
All exercise variables were described using measures of central tendency and dispersion.
Normally distributed data was described using mean + standard deviation. Abnormally
distributed data was described via median and interquartile range (IQR). Categorical variables
were assessed using Chi‐square analysis. A one‐way analysis of variance (ANOVA) equal
variance F‐test was employed to assess for differences between the three HF groups for the
following variables: peak VO2, VAT, peak RER, VE/VCO2 slope, OUES, EOV, and PetCO2 values at
rest, during exercise at the VAT and peak exercise. Tukey’s HSD test for multiple comparisons
was used to determine wherein the difference lies when a significant difference was detected.
Additionally, within group correlation was performed to assess for potential associations
between peak VO2 and the described clinical characteristics and the remaining common clinical
CPET variables. A post‐hoc analysis of covariance (ANCOVA) was also performed to determine
if there were significant main effects for peak VO2 and if there was a significant interaction
between hemoglobin and peak VO2 between the heart failure groups. A p‐value of < .05 was
used for significance. JMPv9® statistical software (SAS Institute Inc., Cary, NC) was utilized for
statistical analysis.
Results
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The clinical characteristics of the three HF groups are displayed in Table 1. There was a
significant difference in BMI between the groups (F (2, 42) = 3.3, p‐value = 0.0463). Specifically,
the TAH group BMI was 6.1 units lower than the HMII group (p‐value = 0.0471, SE = 2.47, 95%
CI’s (0.07 – 12.08). BMI was similar between the ESHF and HMII groups although it is noted
they both would be classified as obese. Hemoglobin (Hgb) concentration was also significantly
different between the groups (F (2, 42) = 52.4, p‐value = <0.0001). Hemoglobin was
significantly lower in both MCS device groups compared with the ESHF group. TAH hemoglobin
was 5.8 mg/dL lower than ESHF (p‐value = <0.0001, SE = 0.59, 95% CI’s (4.4 – 7.3), whereas
HMII hemoglobin was 4.1 mg/dL lower than ESHF (p‐value = <0.0001, SE = 0.59, 95% CI’s (2.7 –
5.6). Additionally, TAH Hgb was significantly lower than HMII (Mean Diff. = 1.7 mg/dL, p‐value =
0.0234, SE = 0.62, 95% CI’s (0.2 – 3.2). Beta‐blocker usage was also different between the
groups as this medication is not part of the pharmacologic regimen in the TAH patient. No
significant difference was observed in beta‐blocker usage between the other two groups.
Aldosterone antagonist usage was significantly different between the groups due to less TAH
patient usage (Chi‐square = 6.3, df = 2, p‐value = 0.0427). Alternatively, calcium channel
blocker use was higher in the TAH patients (Chi‐square = 11.8, df = 2, p‐value = 0.0027).
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Table 1: Clinical Characteristics of HF Groups
TAH (n = 14)
Age (years)

HMII (n = 14)

ESHF (n = 17)

p ‐ value

43 (38 ‐ 53)

53 (37 ‐ 59)

59 (41 ‐ 65)

0.4421

Gender (M,F)

9,5

9,5

15,2

0.1846

Race (C,AA,O)

9,4,1

7,7,0

10,7,0

0.4887

HF Etiology

0.1749
NICM

13

10

10

ICM

1

4

6

CHD

0

0

1

a

33.6 + 8.0

32.1 + 5.9

*0.0463

a

b

13.7 + 2.0

*<.0001

21 + 10

16 + 8

0.1583

2

BMI (kg/m )

27.5 + 5.5
7.9 + 1.4

Hgb (mg/dL)
LVEF (%)

9.6 + 1.5

Indication for MCS
BTT

14 (100%)

8 (52%)

DT

4 (29%)

BTD

2 (14%)

Post‐op day of CPET (#)

46 (35 ‐ 100)

61 (49 ‐ 95)

0.9876

Comorbidities (n, %)
DM

3 (21%)

5 (36%)

5 (29%)

0.7014

PVD

1 (7%)

3 (21%)

3 (18%)

0.5212

Smoker

2 (14%)

1 (7%)

0

0.1868

COPD

0

2 (14%)

0

0.0871

Pacemaker

0

5 (36%)

6 (35%)

0.9806

3 (21%

7 (41%)

0.2363

14 (100%)

15 (82%)

0.1321

0

13 (93%)

17 (100%)

a

11 (79%)

15 (88%)

*<0.001

ACE‐I

6 (43%)

8 (57%)

9 (53%)

0.7371

ARB

0

1 (7%)

4 (24%)

0.0596

Anti‐Aldosterone

a

3 (21%)

8 (57%)

11 (65%)

*0.0427

CCB

6 (43%)

a

1 (7%)

0

*0.0027

HDZN/ISDN

2 (14%)

0

0

0.0871

Other*

1 (7%)

1 (7%)

0

0.3764

* Nesiritide

*Sildenafil

Atrial fibrillation
Sedentary

14 (100%)

Therapies (n, %)
AICD
B‐blocker

a

0

= significant difference between HMII and ESHF(p <.05), b = sig. difference between ESHF (p <.05)
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Table 2 lists MCS device specific parameters at the time of CPET. These parameters
were set prior to CPET by the attending cardiologist/cardiothoracic surgeon to optimize clinical
condition. TAH driver was the type of driver utilized at time of CPET. Right and left‐drive
pressure is the amount of air entering the respective artificial ventricles for ejection. % systole
is the percent of the cardiac cycle spent in systole. Beat rate is the pump rate or heart rate of
the device. In the HMII, pump speed is the set speed in revolutions per minute (rpm) of the
rotor assembly housed within the pump.
Table 2: MCS Device Specific Variables
TAH
TAH driver (n, %)
Big‐Blue Driver

10 (71%)

Freedom Driver

4 (29%)

RDP (mmHg)

83 (74 ‐ 110)

LDP (mmHg)

205 (199 ‐ 210)

% Systole (%)
Beat rate (bpm)

53 (50 ‐ 60)
130 (120 ‐ 138)
HMII

Pump speed (rpm)

9671 + 487

Abbreviations: RDP= Right drive pressure, LDP=Left drive pressure
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Table 3 shows the mean + SD by HF group for standard exercise test variables. All of the
exercise tests were symptom‐limited in nature and were terminated by patient request to stop.
No adverse events occurred with any of the CPET’s performed in this very high‐risk patient
population. Reasons for test termination are provided with (n, %) for primary symptomology
within each group. There was a significant difference noted in peak exercise mean arterial
pressure (MAP) (F (2, 42) = 6.1, p‐value = 0.0048) and peak Borg rating of perceived exertion
(RPE) 6 – 20 scale (F (2, 42) = 4.6, p‐value = 0.0151). Specifically, the HMII peak MAP was
15mmHg higher than the TAH group (p‐value = 0.04, SE = 6.2, 95% CI’s (0.6 – 31) and 20mmHg
higher than the ESHF (p‐value = 0.0045, SE = 5.9, 95% CI’s (5.5 – 34) and peak Borg RPE was
significantly higher (1.5 units) in the ESHF group compared with TAH patients (p‐value = 0.022,
SE = 0.5, 95% CI’s (0.2 – 2.8).
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Table 3: Standard Exercise Test Variables
TAH

HMII

ESHF

p‐value

Exercise Time (min)

5.6 + 1.2

5.3 + 2.2

6.7 + 2.7

0.1765

RHR (bpm)

128 + 6a

82 + 12

78 + 19

*<0.0001

Peak HR (bpm)

128 + 6

117 + 20

120 + 21

0.2241

Resting MAP (mmHg)

89 + 11

86 + 10

81 + 14

0.1743

Peak MAP (mmHg)

87 + 14

102 + 15b

82 + 19

*0.0048

Peak RPE (6 ‐ 20)

14.5 + 0.7

14.7 + 1.7

16.0 + 1.8c

*0.0151

Peak RPD (0 ‐ 10)

4.4 + 1.8

3.9 + 2.0

5.6 + 2.1

0.0711

DOE

4 (29%)

7 (50%)

7 (41%)

General Fatigue

2 (14%)

4 (29%)

4 (24%)

LE Fatigue

6 (43%)

2 (14%)

4 (24%)

Other

2 (14%)

1 (7%)

2 (11%)

Test Termination

a

= sig. between HMII and ESHF (p<.05), b = sig. difference between TAH and ESHF, c = sig. difference between TAH

CPET Variables
Table 4 describes the mean + SD values for the variables obtained from CPET in the
different groups. A significant difference was noted between groups for peak oxygen
consumption (L∙min) (F (2, 42) = 7.9, p‐value = 0.0012) and percentage of predicted peak
oxygen consumption (F (2, 42) = 5.1, p‐value = 0.0106) when expressed in absolute terms, but
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not relative to bodyweight (mL∙kg−1∙min−1) (p‐value = 0.08). Similarly, there was a significant
difference in ventilatory anaerobic threshold values (F (2, 33) = 8.7, p‐value = 0.0009) and VAT
percent of predicted peak VO2 (F (2, 33) = 5.0, p‐value = 0.0125) between the three groups for
absolute values, but not for relative values (p‐value = 0.056) although there was a trend
towards lower relative peak VO2 values in the TAH group. Specifically, the TAH group had
significantly lower absolute peak oxygen consumption, percentage of predicted peak oxygen
consumption, absolute ventilatory anaerobic threshold, and VAT percent of predicted peak VO2
compared with the other two groups. Additionally, the TAH group had a significantly higher
peak RER (F (2, 42) = 14.1, p‐value = <0.0001), and a lower oxygen uptake efficiency slope (F (2,
42) = 9.3, p‐value = 0.0004). No significant difference was found between the HMII and ESHF
groups for peak VO2, % predicted peak VO2, VAT, VAT % predicted of peak VO2, RER, and OUES.
The ESHF group did have a significantly higher presence of EOV (Chi‐square = 7.73, df = 2, p‐
value = 0.0228) than either MCS device group. No significant difference was noted in the
VE/VCO2 slope between groups although the TAH group trended towards a higher value. No
significant difference was noted in PetCO2 values at rest, VAT, or peak exercise between the
groups. However, it is noted that a flat PetCO2 response to exercise was observed in all three
groups.
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Table 4: Descriptive CPET Variables
TAH

ESHF

p‐value

0.926 + .168a

1.270 + .364

1.340 + .331

*0.0012

36 + 8a

49 + 12

50 + 17

*0.0106

11.0 + 2.3

12.6 + 2.8

13.9 + 4.7

0.0800

33 + 7

40 + 14

44 + 16

0.1051

Peak METs

3.1 + 0.7

3.6 + 0.8

4.0 + 1.3

0.0777

VAT (L∙min)

0.706 + .181a

1.008 + .252

0.996 + .201

*0.0009

27 + 7a

37 + 10

38 + 12

*0.0125

8.4 + 2.5

10.0 + 2.1

10.6 + 2.2

0.0566

25 + 7

30 + 15

33 + 10

0.1997

Peak RER

1.30 + 0.09a

1.12 + 0.14

1.1 + 0.11

*<.0001

OUES

0.96 + 0.25a

1.69 + 0.52

1.58 + 0.59

*0.0004

39.8 + 8.0

34.1 + 6.6

34.9 + 7.6

0.0968

4 (29%)

4 (29%)

12 (71%)b

*0.0228

PetCO2 @ Rest (mmHg)

33.6 + 3.2

34.3 + 3.5

34.2 + 3.9

0.8804

PetCO2 @ VAT (mmHg)

32.5 + 3.0

33.9 + 3.9

34.8 + 4.8

0.3084

PetCO2 @ Peak (mmHg)

29.1 + 4.2

32.2 + 4.3

31.2 + 5.8

0.2315

Peak VO2 (L∙min)
% Pred. VO2
Peak VO2 (ml.kg.min)
% Pred. VO2

% Pred. peak VO2
VAT (ml.kg.min)
% Pred. peak VO2

VE/VCO2 slope
Presence of EOV

a

HMII

= sig. difference between HMII and ESHF (p <.05), b = sig. difference between TAH and HMII
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Figure 1 provides a visual depiction of the difference in peak oxygen consumption
between the three groups. The mean diamonds show the respective mean and 95% CI’s. The
hash marks represent the standard deviations.

2

Peak VO2 (L/min)

1.75

1.5

1.25

1

0.75

ESHF

HMII
Heart Failure Group

Figure 1: Peak VO2 by Heart Failure Group
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TAH

Table 5 is a contingency table based on the objective risk stratification classification
systems commonly employed to stratify heart failure severity and guide clinical management.
No significant difference was noted between the groups although TAH patients tended to fall
into lower Weber functional classes and higher ventilatory classes.
Table 5: Weber Functional & Ventilatory Class Schema
TAH

HMII

ESHF

Weber Class
A

0

0

2 (12%)

B

0

4 (29%)

4 (24%)

C

9 (64%)

7 (50%)

8 (47%)

D

5 (36%)

3 (21%)

3 (18%)

I

0

4 (29%)

5 (29%)

II

6 (43%)

5 (36%)

6 (35%)

III

4 (28.5%)

4 (21%)

3 (18%)

IV

4 (28.5%)

1 (7%)

3 (18%)

Ventilatory Class

Correlation analysis demonstrated there was a significant positive association between
the clinical characteristics of body mass index (r = 0.36, df = 43, p‐value = 0.0159) and
hemoglobin concentration (r = 0.62, df = 43, p‐value = <0.0001) with absolute peak oxygen
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uptake. After controlling for HF group assignment, HMII was the only group which retained a
significant association between BMI and peak VO2. Similarly, there was a significant association
observed between gender and peak VO2 in the HMII group only (t = 2.28, df = 12, p‐value =
0.0419) with females having a peak VO2 of 0.402 L∙min less than the males (p‐value = 0.0419, SE
= 0.18, 95% CI’s (0.02 ‐ 0.79). Hemoglobin concentration had a significant positive association
within all three HF groups: TAH (r = 0.57, df = 12, p‐value = 0.0347), HMII (r = 0.66, df = 12, p‐
value = 0.0102), ESHF (r = 0.70, df=15, p‐value = 0.0018). OUES also showed a significant
positive correlation with peak oxygen uptake (r = 0.71, df = 43, p‐value = <0.0001).
An ANCOVA model indicated there were significant main effects for peak VO2 due to HF
group and hemoglobin concentration (F(5,39) = 7.66, p‐value = <0.0001). However, there was
not a significant interaction effect found between peak VO2 and hemoglobin between the heart
failure groups.
Discussion
Exercise capacity is indeed reduced in TAH patients. Peak exercise oxygen consumption,
percentage of predicted peak VO2, and oxygen consumption at the ventilatory anaerobic
threshold is reduced in TAH patients compared with HMII LVAD patients as well as those with
advanced heart failure on medical‐management only awaiting heart transplant. This is
accompanied by a significant elevation in peak exercise RER values and a significant reduction in
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the OUES. Additionally, there was a significantly blunted peak exercise mean arterial pressure
for the TAH group compared to the HMII group. Not surprisingly, hemoglobin status at the time
of CPET appears to significantly affect exercise capacity in all HF groups.
In this study all three groups exhibited very low peak VO2 values consistent with
significant advanced heart failure which is similar to that previously reported in non‐MCS
patients.43, 44 Although it must be noted the peak oxygen consumption and ventilatory
anaerobic threshold values observed in the MCS device groups (TAH, HMII) were both
somewhat lower than that previously cited by others particularly when referenced to
bodyweight.45‐47 This may be somewhat misleading in the HMII group due to the excessive BMI
values (BMI = 33.6 + 8) observed in this cohort compared with that reported by others.45, 48 For
example, de Jonge and colleagues reported peak VO2 values of 22.8 ml.kg‐1.min‐1 in LVAD
patients 3 months after implant with a mean BMI of 22. Haft et al. observed a peak VO2 of 15.6
+ 4.7 ml.kg‐1.min‐1 in a group of HMII LVAD recipients with a BMI of 27 + 6.
In comparison to the only other study evaluating CPET variables in the TAH patient by
Bellotto et al., the absolute peak VO2 and VO2 at the ventilatory anaerobic threshold of TAH
patients in our study was similar to that observed in the first CPET (0.945 L∙min, 0.666 L∙min,
respectively) performed by their subject at approximately 3 months following TAH implant. Of
note, the single subject in the Bellotto study was normal weight evidenced by BMI status (BMI =
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22) and had a hemoglobin 2.2 g/dL higher than the average observed in the present study.23
During this same test an elevated peak RER was also observed (RER = 1.32) along with a flat
blood pressure response consistent with that noted in this study. Conversely, the Bellotto
subject displayed normal VE/VCO2 slope values (26.51 – 29.09) across all four sequential CPET’s
although the present investigation observed an elevated VE/VCO2 slope consistent with a
Ventilatory Class III rating indicative of a poor prognosis in HF patients.16
The blunted blood pressure response noted in the TAH group is similar to that
previously reported by Kohli and colleagues. 24 The present study differs in that the MAP values
were obtained with maximal exercise testing versus a submaximal assessment during an
exercise session. This confirms that the blood pressure response observed is potentially related
to the limitations of the TAH device and not exercise intensity. Interestingly, the average
exercise training intensity noted in the Kohli study (2.3 + 0.5 METs) is similar to the mean MET
level (2.4 METs) at the VAT observed in the present study. This may indicate the average
exercise workloads observed by Kohli might represent the highest sustainable exercise intensity
capable in this population.
The Fick equation (VO2 = Cardiac Output x a‐VO2 difference) demonstrates that VO2 is
largely dependent upon increases in cardiac output. It is universally accepted that maximal
cardiac output is the major determinant of maximal oxygen uptake during exercise.49 Factors
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that determine oxygen uptake with exercise include: 1) pulmonary diffusing capacity, 2)
maximal cardiac output, 3) oxygen carrying capacity of the blood, and 4) skeletal muscle
characteristics (i.e. O2 extraction capabilities of muscle).49 Previous work in MCS patients has
shown that the device is responsible for the majority of the cardiac output increase seen during
exercise.50, 51 The TAH patient has a fixed pump rate (i.e. heart rate) with exercise thus has a
fairly fixed cardiac output response to exercise. The only augmentation of cardiac output is
derived via enhanced venous return by the skeletal muscle blood pump during exercise and
compensatory venoconstriction.21, 52 Bellotto observed a limited cardiac output response in the
TAH patient on the order of a 1.6 to 2.9 L/min increase with peak exercise.23
The TAH patient peak oxygen uptake values noted in the present study approximate a
three‐fold increase above resting metabolism (METS = 3.1 + 0.7). When cardiac output is
unchanged oxygen uptake can only increase approximately three‐fold due to the limits of
maximal oxygen extraction with exercise.33 As the ability to increase cardiac output decreases,
the a‐VO2 diff. has a greater influence on the VO2 response to exercise. In healthy individuals,
a‐VO2 diff. is approximately 5ml/100mL blood at rest and can increase to approximately 15
ml/100mL blood at maximum exercise. This, however, is also dependent upon hemoglobin
status and hemoconcentration with exercise. Anemia is known to be common in heart failure
and associated with poor outcome and reduced exercise capacity.53 Agostoni and colleagues
evaluated the relationship between hemoglobin and peak VO2 in heart failure patients.54 They
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found anemic patients had lower peak VO2, VO2 at the anaerobic threshold, and a higher
VE/VCO2 slope than non‐anemic HF patients. Their linear regression slope demonstrated that
each gram of hemoglobin accounted for a 109 ml.min change in VO2 (0.97 ml.kg.min). Using the
assumption of Agostoni, and all other things being equal, the TAH group in the present study
could potentially improve peak VO2 > 0.5 L∙min if hemoglobin was treated to a level exhibited
in the ESHF group.
Another observation from this study was the continued presence of an oscillatory
breathing pattern with exercise in both MCS device groups. The frequency is similar to that
observed in other studies of chronic heart failure patients.19, 39 The prognostic significance of
this finding is unclear in the MCS device population, but underscores the multifactorial
pathophysiology of this phenomenon.
Obvious limitations of this study were the low number of participants affecting validity
although it is noted the number of MCS device patients in this study is similar to others in the
literature in this novel population. A significant proportion of the original MCS cohort was not
available for CPET (36% TAH, 44% HMII) due to medical status, low functional status, or
unavailability (i.e. underwent heart transplant, lost‐to follow up) which may have affected the
representativeness of the sample population. This was only a cross‐sectional study examining
the exercise capacity of MCS patients relatively early after device implant. The postoperative
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date (POD#) of CPET was smaller than that recommended for optimal functional results in the
post‐MCS patient.45 The mean POD# for TAH and HMII was 46 days (~6.7 weeks) and 61 days
(~8.7 weeks) where as deJonge and others have observed optimal timing for CPET was at least
12 weeks post‐implant.45, 47
Implications/ Recommendations
The persistently low exercise capacity following MCS device implant, particularly the
TAH device necessitates the need for strategies to further improve functional status in these
individuals. This low functional status needs to be considered when examining the exertional
symptoms or ADL tolerance of these patients. Furthermore, the presence of CPET variables
with strong prognostic significance in the heart failure population (i.e. low peak VO2, low VAT,
high VE/VCO2 slope, low OUES, blunted PetCO2 response to exercise, low peak blood pressure,
presence of EOV) persist in the short‐term following MCS device implantation although their
clinical importance in this population is unknown.
Efforts to improve the persistent significant anemia seen in the TAH patient will help to
improve oxygen extraction and utilization during exercise thus augmenting oxygen
consumption and functional status. Aerobic exercise training will also likely improve exercise
capacity via a peripheral adaptation (i.e. increased a‐VO2 difference). Future studies should
examine the correlation between the auto‐regulated cardiac output and fill‐volumes (stroke
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volume) derived from the TAH and oxygen consumption. This may shed light on optimal device
settings with exercise. Furthermore, the effects of up‐titrating the TAH beat rate during
exercise to augment cardiac output similar to the normal intrinsic heart rate increase with
exercise requires further study.
Summary/Conclusions
This is the first study to directly measure the maximal exercise capacity in a group of
advanced heart failure patients supported with total artificial heart. Additionally, this study
compared the responses to graded exercise in TAH patients with both a group of patients
implanted with a HMII left ventricular assist device and a group of patients with advanced heart
failure being assessed for transplant. Based on these findings, symptom‐limited exercise
testing can be safely performed in the TAH patient. The exercise capacity of the TAH patient is
reduced compared with other MCS devices and in those with advanced heart failure. We now
have a baseline for expected functional ability and exercise responses in this unique patient
population. This may facilitate formulation of appropriate functional goals and exercise
prescription guidelines in the rehabilitation setting. It will help inform discussions of activity
guidelines for those entering the community in light of a current FDA trial using a portable
driver. It may also provide an objective reference for future technology improvements.
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Appendix 2

Table 1: Significant Differences of CPET Variables between HF groups
Comparison
ESHF ‐ TAH
HMII ‐ TAH
ESHF ‐ HMII

Peak VO2 (L•min)
Difference
SE
0.415 0.1092
0.345 0.1144
0.070 0.1092

Lower CL
0.149
0.067
‐0.196

Upper CL
0.680
0.623
0.335

% predicted Peak VO2 (L•min)
Difference
SE Lower CL Upper CL
14.0
4.70
2.5
25.4
12.5
4.92
0.5
24.5
1.5
4.70
‐10.0
12.9
VAT (L•min)
Comparison
Difference
SE Lower CL Upper CL
HMII ‐ TAH
0.302 0.0886
0.085
0.519
ESHF ‐ TAH
0.291 0.0799
0.095
0.487
HMII ‐ ESHF
0.011 0.0899
‐0.209
0.232
VAT (% predicted Peak VO2
(L•min))
Comparison
Difference
SE Lower CL Upper CL
ESHF ‐ TAH
10.8
3.69
1.7
19.9
HMII ‐ TAH
9.7
4.09
‐0.4
19.7
ESHF ‐ HMII
1.1
4.15
‐9.1
11.3
Peak RER
Comparison
Difference
SE Lower CL Upper CL
TAH ‐ ESHF
0.205 0.0412
0.104
0.305
TAH ‐ HMII
0.181 0.0432
0.076
0.286
HMII ‐ ESHF
0.023 0.0412
‐0.077
0.123
OUES
Comparison
Difference
SE Lower CL Upper CL
HMII ‐ TAH
0.731 0.1830
0.286
1.175
ESHF ‐ TAH
0.612 0.1748
0.187
1.036
HMII ‐ ESHF
0.119 0.1748
‐0.306
0.544
Presence of EOV
Likelihood ratio chi‐square = 7.73, df = 2, p‐Value = 0.021
Comparison
ESHF ‐ TAH
HMII ‐ TAH
ESHF ‐ HMII
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p‐Value
0.0013
0.0119
0.7995
p‐Value
0.0133
0.0388
0.9481
p‐Value
0.0048
0.0026
0.9911

p‐Value
0.0165
0.0606
0.9608
p‐Value
<.0001
0.0004
0.8407
p‐Value
0.0007
0.0031
0.7759
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